

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number
WO 02/079249 A2

(51) International Patent Classification⁷: **C07K 14/56**,
C12Q 1/68, C07K 16/18, C12N 15/10, 15/85, 5/10

(21) International Application Number: PCT/EP02/04082

(22) International Filing Date: 29 March 2002 (29.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01/04404 30 March 2001 (30.03.2001) FR

(71) Applicant (*for all designated States except US*): **GEN-ODYSSEE** [FR/FR]; Parc d'Affaires Technopolis, 3, avenue du Canada, Bat. Alpha, BP 810 Les Ulis, F-91974 Courtaboeuf (FR).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **ESCARY, Jean-Louis** [FR/FR]; 4, rue Moxouris, F-78510 Le Chesnay (FR).

(74) Agent: **RINUY, Santarelli**; 14, avenue de la Grande-Armée, B.P. 237, F-75822 Paris (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN α (A)-21 GENE

(57) Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN α -21 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN α -21 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

WO 02/079249 A2

NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN α -21 GENE

RELATED APPLICATIONS:

The present invention claims priority to French Patent Application 0104404 filed on
5 30 March 2001 titled <<Nouveaux polynucléotides comportant des polymorphismes de type
SNP fonctionnels dans la séquence nucléique du gène IFN α 21 ainsi que de nouveaux
polypeptides codés par ces polynucléotides et leurs utilisations thérapeutiques.>>

BACKGROUND OF THE INVENTION

10 *Field of the Invention.*

The present invention relates to new polynucleotides derived from the nucleotide
sequence of the IFN α -21 gene comprising new SNPs, and new polypeptides derived from the
natural wild-type IFN α -21 protein comprising mutations caused by these SNPs, as well as
their therapeutic uses.

15

Related Art.

The interferon alpha 21 gene, hereinafter referred to as IFN α -21, is described in the
publications:

- Goeddel, D. V., Leung, D. W; "The structure of eight distinct cloned human
20 leukocyte interferon cDNAs"; Nature 290 (5801), 20-26 (1981).
- Olopade OI., Bohlander SK.; "Mapping of the shortest region of overlap of
deletions of the short arm of chromosome 9 associated with human neoplasia"; Genomics 14
(2), 437-443 (1992).

The nucleotide sequence of this gene is accessible in the HTG section of the GenBank
25 database under accession number AC009445.

The sequence of the messenger RNA of IFN α -21 is mentioned in the database of the
NCBI, under accession code NM_002175.

IFN α -21 is a gene possessing a structural and functional homology close to that of
human interferons alpha (IFN α), specifically IFN α -2.

30 The IFN α are known for their cellular antiproliferative effects and their involvements
in antiviral and antiparasitic responses.

The IFN α are also known to inhibit the expression of several other cytokines at the
level of the hematopoietic stem cells, as well as to inhibit the cellular proliferation of certain

tumors.

The IFN α are also known to reduce the expression of the receptors to the EGF in renal carcinomas, to inhibit the expression of certain mitochondrial genes, to inhibit the proliferation of fibroblasts, monocytes and B lymphocytes, especially *in vitro*, and to block
5 the synthesis of antibodies by B lymphocytes.

The IFN α are also known to induce the expression of tumor specific antigens on the surface of tumor cells and also to induce the genes placed under the control of promoter regions of the ISRE type (Interferon-Stimulated Response Element) by acting on the specific transcription factors of these ISRE.

10 It is known that the IFN α are involved in different disorders and/or human diseases, such as the different cancers like for example, carcinomas, melanomas, lymphomas, leukemias and cancers of the liver, neck, head and kidneys, cardiovascular diseases, metabolic diseases such as those that are not connected with the immune system like, for example, obesity, infectious diseases such as hepatitis B and C and AIDS, pneumonias,
15 ulcerative colitis, diseases of the central nervous system like, for example, Alzheimer's disease, schizophrenia and depression, the rejection of tissue or organ grafts, healing of wounds, anemia in dialyzed patients, allergies, asthma, multiple sclerosis, osteoporosis, psoriasis, rheumatoid arthritis, Crohn's disease, autoimmune diseases and disorders, gastrointestinal disorders or even disorders connected with chemotherapy treatments.

20 The IFN α are particularly used for the treatment of certain leukemias, metastasized renal carcinomas as well as tumors that appear following an immunodeficiency, such as Kaposi's sarcoma in the case of AIDS. The IFN α are also effective against other types of tumors and against certain viral infections. The IFN α are also recognized by the FDA (Food and Drug Administration) for the treatment of genital warts or venereal diseases.

25 More specifically, IFN α -21 was located by *in situ* hybridization in the brains of patients suffering from Parkinson's disease or Alzheimer's disease.

Compared to other cells, microglial cells express IFN α -21 in large quantities.

In patients suffering from Alzheimer's disease, the presence of IFN α -21 was shown in the neurons of the parietal lobes, suggesting that IFN α -21 may be involved in this
30 pathology (See e.g. Kawaguchi N, Yamada T, Yoshiyama Y. No To Shinkei. 1997 Jan.; 49(1): 69-73).

However, the IFN α , and in particular IFN α -21, have numerous side effects when they are used in pharmaceutical compositions, such as reactions of acute hypersensitivity

(urticaria, bronchoconstriction, anaphylactic shock etc.), cardiac arrhythmias, low blood pressure, epileptic seizures, problems with thyroid functions, flu-like syndromes (fevers, sweats, myalgias) etc.

Furthermore, the patients treated with IFN α can develop antibodies neutralizing these
5 molecules, thus decreasing their effectiveness.

The inventors have found new polypeptide and new polynucleotide analogs to the IFN α -21 gene capable of having a different functionality from the natural wild-type IFN α -21 protein.

These new polypeptides and polynucleotides can notably be used to treat or prevent
10 the disorders or diseases previously mentioned and avoid all or part of the disadvantages, which are tied to them.

BRIEF SUMMARY OF THE INVENTION

The invention has as its first object new polynucleotides that differ from the
15 nucleotide sequence of the reference wild-type IFN α -21 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism).

The nucleotide sequence SEQ ID NO. 1 of the human reference wild-type IFN α -21 gene is composed of 2001 nucleotides and comprises a coding sequence of 570 nucleotides, from nucleotide 670 (start codon) to nucleotide 1239 (stop codon).

20 The applicant has identified 8 SNPs in the nucleotide sequence of the reference wild-type IFN α -21 gene. These 8 SNPs are the following: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c.

It is understood, in the sense of the present invention, that the numbering corresponding to the positioning of the SNP previously defined is relative to the numbering
25 of the nucleotide sequence SEQ ID NO. 1.

The letters a, t, c and g correspond respectively to the nitrogenous bases adenine, thymine, cytosine and guanine.

The first letter corresponds to the wild-type nucleotide, whereas the last letter corresponds to the mutated nucleotide.

30 Thus, for example, the SNP c794g corresponds to a mutation of the nucleotide cytosine (c) at position 794 of the nucleotide sequence SEQ ID NO. 1 of the reference wild-type IFN α -21 gene, into nucleotide guanine (g).

These SNPs were identified by the applicant using the determination process

described in applicant's patent application FR 00 22894, entitled "Process for the determination of one or several functional polymorphism(s) in the nucleotide sequence of a preselected functional candidate gene and its applications" and filed December 6, 2000, cited here by way of reference.

5 The process described in this patent application permits the identification of one (or several) preexisting SNP(s) in at least one individual from a random population of individuals.

10 In the scope of the present invention, a fragment of the nucleotide sequence of the IFN α -21 gene, comprising, for example, the coding sequence, was isolated from different individuals in a population of individuals chosen in a random manner.

Sequencing of these fragments was then carried out on certain of these samples having a heteroduplex profile (that is a profile different from that of the reference wild-type IFN α -21 gene sequence) after analysis by DHPLC ("Denaturing-High Performance Liquid Chromatography").

15 The fragment sequenced in this way was then compared to the nucleotide sequence of the fragment of the reference wild-type IFN α -21 gene and the SNPs in conformity with the invention identified.

Thus, the SNPs are natural and each of them is present in certain individuals of the world population.

20 The reference wild-type IFN α -21 gene codes for an immature protein of 189 amino acids, corresponding to the amino acid sequence SEQ ID NO. 2, that will be converted to a mature protein of 166 amino acids, by cleavage of the signal peptide that includes the first 23 amino acids.

25 Each of the coding SNPs of the invention, namely: c794g, c973a, g1011c, t1049a, t1155a, a1204g, causes modifications, at the level of the amino acid sequence, of the protein encoded by the nucleotide sequence of the IFN α -21 gene.

These modifications in the amino acid sequence are the following:

30 The SNP c794g causes a mutation of the amino acid alanine (A) at position 42 in the immature protein of the IFN α -21 gene, corresponding to the amino acid sequence SEQ ID NO. 2, in glycine (G) and at position 19 of the mature protein. In the description of the present invention, one will call the mutation encoded by this SNP either A19G or A42G according to whether one refers to the mature protein or to the immature protein respectively.

The SNP c973a causes a mutation of the amino acid glutamine (Q) at position 102 in

the immature protein of the IFN α -21 gene, corresponding to the amino acid sequence SEQ ID NO. 2, in lysine (K) and at position 79 of the mature protein. In the description of the present invention, one will call the mutation encoded by this SNP Q79K or Q102K according to whether one refers respectively to the mature protein or to the immature protein.

5 The SNP g1011c causes a mutation of the amino acid glutamine (Q) at position 114 in the immature protein of the IFN α -21 gene, corresponding to the amino acid sequence SEQ ID NO. 2, in histidine (H) and at position 91 of the mature protein. In the description of the present invention, one will call the mutation encoded by this SNP Q91H or Q114H according to whether one refers respectively to the mature protein or to the immature protein.

10 The SNP t1049a causes a mutation of the amino acid valine (V) at position 127 in the immature protein of the IFN α -21 gene, corresponding to the amino acid sequence SEQ ID NO. 2, in aspartic acid (D) and at position 104 of the mature protein. In the description of the present invention, one will call the mutation encoded by this SNP V104D or V127D according to whether one refers respectively to the mature protein or to the immature protein.

15 The SNP t1155a causes a mutation of the amino acid cysteine (C) at position 162 in the immature protein of the IFN α -21 gene, corresponding to the amino acid sequence SEQ ID NO. 2, in stop codon (stop) and at position 139 of the mature protein. In the description of the present invention, one will call the mutation encoded by this SNP C139stop or C162stop according to whether one refers respectively to the mature protein or to the immature protein.

20 The SNP a1204g causes a mutation of the amino acid lysine (K) at position 179 in the immature protein of the IFN α -21 gene, corresponding to the amino acid sequence SEQ ID NO. 2, in glutamic acid (E) and at position 156 of the mature protein. In the description of the present invention, one will call the mutation encoded by this SNP K156E or K179E according to whether one refers respectively to the mature protein or to the immature protein.

25 The SNPs c794g, c973a, g1011c, t1049a, t1155a, a1204g cause modifications of the spatial conformation of the polypeptides in conformity with the invention compared to the polypeptide encoded by the nucleotide sequence of the wild-type reference IFN α -21 gene.

These modifications can be observed by computational molecular modeling, according to methods that are well known to a person skilled in the art, making use of, for example, the modeling tools *de novo* (for example, SEQFOLD/MSI), homology (for example, MODELER/MSI), minimization of the force field (for example, DISCOVER, DELPHI/MSI) and/or molecular dynamics (for example, CFF/MSI).

Examples of such models are given hereinafter in the experimental section.

Computational molecular modeling shows that the mutation Q79K on the mature mutated protein involves the displacement of helix C N-end in the wild-type IFN α -21 protein due to hydrogen bonds disturbance as shown in Figures 1A and 1B.

Indeed, hydrogen bonds between the oxygen atom of Q79 residue's side chain, E83 residue's acidic group and helix C of the wild-type IFN α -21 protein disappear in the Q79K mutated IFN α -21 protein.

Thus, the Q79K mutated protein possesses a three-dimensional conformation different from the natural wild-type IFN α -21 protein involving a significant change in its structure and function.

Computational molecular modeling shows that the mutation Q91H on the mature mutated protein involves a displacement of helix C at the mutation position as shown in Figures 2A and 2B. Several hydrogen bonds and salt bridges appear, especially between H91 and D76 amino acids side chains, which make the helix more rigid.

Thus, the Q91H mutated protein possesses a three-dimensional conformation different from the natural wild-type IFN α -21 protein involving a significant change in its structure and function.

Computational molecular modeling shows that the mutation V104D on the mature mutated protein involves modifications in the structure of the loop between helices C and D at the mutation position as shown in Figures 3A and 3B. In the mutated structure several hydrogen bonds appear (between Q102 and G105 on the one hand, and Q52, E107 and T109 on the other hand) which make the loop between helices C and D more rigid. Moreover, a slight displacement of helix B N-end is also observed.

These spatial modifications affect the residues involved in IFN α -21 binding to its receptor.

Thus, the V104D mutated protein possesses a three-dimensional conformation different from the natural wild-type IFN α -21 protein involving a significant change in its structure and function.

Computational molecular modeling shows that the mutation C139stop on the mature mutated protein causes a premature arrest in protein translation leading to the disappearance of a polypeptidic fragment normally involved in helix E in the wild-type IFN α -21 protein, as shown in Figure 4.

Helix E is essential for IFN α -21 binding to its receptor. The absence of helix E causes an incorrect folding of the mutated protein and leads to a modification in the three-

dimensional conformation of the protein in which the hydrophobe core of the protein is in contact with the hydrophilic external medium. Thus, the mutated protein must modify its three-dimensional conformation so as its hydrophobic core is covered with hydrophilic residues in order to avoid contact with hydrophilic external medium.

5 Thus, the C139stop mutated protein possesses a three-dimensional conformation different from the natural wild-type IFN α -21 protein involving a significant change in its structure and function.

 Computational molecular modeling shows that the mutation K156E on the mature mutated protein involves unfolding of helix E C-end and modification of the C-terminus loop
10 shape as shown in Figures 5A and 5B.

 This mutation increases the hydrogen bonds network and creates a salt bridge between E156 and R161 residues. These modifications render IFN α -21 protein structure more rigid in this area. This area in the protein is known to be involved in its antiviral activity. Thus, it is possible to predict that the K156E mutated IFN α -21 protein's antiviral activity is
15 dramatically disturbed and that the glutamic acid at position 156 causes a modification in the structure and the function of mature IFN α -21.

 Other SNPs in conformity with the invention, namely: t1265c, t1277c do not involve modification of the protein encoded by the nucleotide sequence of the IFN α -21 gene at the level of the amino acid sequence SEQ ID NO. 2. The SNPs t1265c, t1277c are non-coding.

20 Genotyping of the polynucleotides in conformity with the invention can be carried out in such a fashion as to determine the allelic frequency of these polynucleotides in a population. Examples of genotyping are given, hereinafter, in the experimental section.

 The determination of the functionality of the polypeptides of the invention can equally be carried out by a test of their biological activity.

25 In this regard, it is possible to measure, for example, the anti-proliferative effect on a Daudi cell line of polypeptides in conformity with the invention in comparison with the natural wild-type IFN α -21 protein (Pielher et al. J. Biol. Chem.; Vol. 275, Issue 51, 40425-40433, December 22, 2000; "New structural and Functional Aspects of the type I Interferon-Receptor interaction revealed by comprehensible mutational analysis of the binding
30 interface").

 The invention also has for an object the use of polynucleotides and of polypeptides in conformity with the invention as well as of therapeutic molecules obtained and/or identified

starting from these polynucleotides and polypeptides, notably for the prevention and the treatment of certain human disorders and/or diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figures 1A and 1B represent a model of the encoded protein according to the invention comprising the SNP c973a (Q79K) and the natural wild-type IFN α -21 protein. Figure 1B represents a close up of the model of the inferior part of each one of the proteins represented in Figure 1A.

10 In Figures 1A and 1B, the black ribbon represents the structure of the natural wild-type IFN α -21 protein and the white ribbon represents the structure of the Q79K mutated IFN α -21 protein.

15 Figures 2A and 2B represent a model of the encoded protein according to the invention comprising the SNP g1011c (Q91H) and the natural wild-type IFN α -21 protein. Figure 2B represents a close up of the model of the left part of each of the proteins represented on Figure 2A.

 In Figures 2A and 2B, the black ribbon represents the structure of the natural wild-type IFN α -21 protein and the white ribbon represents the structure of the Q91H mutated IFN α -21 protein.

20 Figures 3A and 3B represent a model of the encoded protein according to the invention comprising the SNP t1049a (V104D) and the natural wild-type IFN α -21 protein. Figure 3B represents a close up of the model of the superior part of each of the proteins represented on Figure 3A.

25 In Figures 3A and 3B, the black ribbon represents the structure of the natural wild-type IFN α -21 protein and the white ribbon represents the structure of the V104D mutated IFN α -21 protein.

30 Figure 4 represents a model of the encoded protein according to the invention comprising the SNP t1155a (C139stop) (Figure 4B) and the natural wild-type IFN α -21 protein (Figure 4A). Figure 4C represents the superposition of the two proteins of figures 4A and 4B. In Figure 4, the black ribbon represents the structure of the natural wild-type IFN α -21 protein and the white ribbon represents the structure of the C139stop mutated IFN α -21 protein.

Figures 5A and 5B represent a model of the encoded protein according to the invention comprising the SNP a1204g (K156E) and the natural wild-type IFN α -21 protein.

Figure 5B represents a close up of the model of the upper part of each of the proteins represented on Figure 5A. In Figure 5, the black ribbon represents the structure of the natural wild-type IFN α -21 protein and the white ribbon represents the structure of the K156E mutated IFN α -21 protein.

Figure 6 represents the survival rate of mice previously infected by VSV virus and treated with A42G, Q114H/V127D, or K179E mutated IFN α -21 protein, in comparison to those treated with wild-type IFN α -2, or those that have not been treated.

In this figure, the abscissas correspond to the time of survival (days) and the ordinates correspond to the relative survival rate of VSV infected mice. The black triangles, the crosses, the black diamonds represent the data for VSV infected mice treated with A42G mutated IFN α -21, Q114H/V127D mutated IFN α -21, and K179E mutated IFN α -21, respectively. The black squares represent the data for VSV infected mice treated with wild-type IFN α -2, and the open triangles represent the data for VSV infected mice that have not been treated.

DETAILED DESCRIPTION OF THE INVENTION

Definitions.

"Nucleotide sequence of the reference wild-type gene" is understood as the nucleotide sequence SEQ ID NO. 1 of the human IFN α -21 gene.

This sequence is accessible in GenBank under Accession number AC009445 and the sequence of the IFN α -21 messenger RNA is mentioned in the database of the NCBI under accession code NM_002175. Moreover, the human IFN α -21 gene is described in Goeddel, D. V., Leung, D. W "The structure of eight distinct cloned human leukocyte interferon cDNAs"; Nature 290 (5801), 20-26 (1981), and Olopade OI., Bohlander SK. "Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia"; Genomics 14 (2), 437-443 (1992).

"Natural wild-type IFN α -21 protein" is understood as the mature protein encoded by the nucleotide sequence of the reference wild-type IFN α -21 gene. The natural wild-type immature protein IFN α -21 corresponds to the peptide sequence shown in SEQ ID NO. 2.

"Polynucleotide" is understood as a polyribonucleotide or a polydeoxyribonucleotide that can be a modified or non-modified DNA or an RNA.

The term polynucleotide includes, for example, a single strand or double strand DNA, a DNA composed of a mixture of one or several single strand region(s) and of one or several double strand region(s), a single strand or double strand RNA and an RNA composed of a mixture of one or several single strand region(s) and of one or several double strand region(s). The term polynucleotide can also include an RNA and/or a DNA including one or several triple strand regions. By polynucleotide is equally understood the DNAs and RNAs containing one or several bases modified in such a fashion as to have a skeleton modified for reasons of stability or for other reasons. By modified base is understood, for example, the unusual bases such as inosine.

"Polypeptide" is understood as a peptide, an oligopeptide, an oligomer or a protein comprising at least two amino acids joined to each other by a normal or modified peptide bond, such as in the cases of the isosteric peptides, for example.

A polypeptide can be composed of amino acids other than the 20 amino acids defined by the genetic code. A polypeptide can equally be composed of amino acids modified by natural processes, such as post translational maturation processes or by chemical processes, which are well known to a person skilled in the art. Such modifications are fully detailed in the literature. These modifications can appear anywhere in the polypeptide: in the peptide skeleton, in the amino acid chain or even at the carboxy- or amino-terminal ends.

A polypeptide can be branched following an ubiquitination or be cyclic with or without branching. This type of modification can be the result of natural or synthetic post-translational processes that are well known to a person skilled in the art.

For example, polypeptide modifications is understood to include acetylation, acylation, ADP-ribosylation, amidation, covalent fixation of flavine, covalent fixation of heme, covalent fixation of a nucleotide or of a nucleotide derivative, covalent fixation of a lipid or of a lipidic derivative, the covalent fixation of a phosphatidylinositol, covalent or non-covalent cross-linking, cyclization, disulfide bond formation, demethylation, cysteine formation, pyroglutamate formation, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodization, methylation, myristoylation, oxidation, proteolytic processes, phosphorylation, prenylation, racemization, seneloylation, sulfatation, amino acid addition such as arginylation or ubiquitination. Such modifications are fully detailed in the literature: PROTEINS-STRUCTURE AND MOLECULAR PROPERTIES,

2nd Ed., T. E. Creighton, New York, 1993, POST-TRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983, Seifter et al. "Analysis for protein modifications and nonprotein cofactors", Meth. Enzymol. (1990) 182: 626-646, and Rattan et al. "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci (1992) 663: 48-62.

"Isolated polynucleotide" or "isolated polypeptide" are understood as a polynucleotide or a polypeptide respectively such as previously defined which is isolated from the human body or otherwise produced by a technical process.

"Identity" is understood as the measurement of nucleotide or polypeptide sequence identity.

Identity is a term well known to a person skilled in the art and well described in the literature. See COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., Ed., Oxford University Press, New York, 1998; BIOCOMPUTING INFORMATICS AND GENOME PROJECT, Smith, D.W., Ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M. and Griffin H.G., Ed, Humana Press, New Jersey, 1994; and SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987.

The methods commonly employed to determine the identity and the similarity between two sequences are equally well described in the literature. See GUIDE TO HUGE COMPUTER, Martin J. Bishop, Ed, Academic Press, San Diego, 1994, and Carillo H. and Lipton D., Siam J Applied Math (1988) 48: 1073.

A polynucleotide having, for example, an identity of at least 95 % with the nucleotide sequence SEQ ID NO. 1 is a polynucleotide which contains at most 5 points of mutation over 100 nucleotides, compared to said sequence.

These points of mutation can be one (or several) substitution(s), addition(s) and/or deletion(s) of one (or several) nucleotide(s).

In the same way, a polypeptide having, for example, an identity of at least 95 % with the amino acid sequence SEQ ID NO. 2 is a polypeptide that contains at most 5 points of mutation over 100 amino acids, compared to said sequence.

These points of mutation can be one (or several) substitution(s), addition(s) and/or deletion(s) of one (or several) amino acid(s).

The polynucleotides and the polypeptides according to the invention which are not totally identical with respectively the nucleotide sequence SEQ ID NO. 1 or the amino acid

sequence SEQ ID NO. 2, it being understood that these sequences contains at least one of the SNPs of the invention, are considered as variants of these sequences.

Usually a polynucleotide according to the invention possesses the same or practically the same biological activity as the nucleotide sequence SEQ ID NO. 1 comprising at least one
5 of the SNPs of the invention.

In similar fashion, usually a polypeptide according to the invention possesses the same or practically the same biological activity as the amino acid sequence SEQ ID NO. 2 comprising at least one of the coding SNPs of the invention.

A variant, according to the invention, can be obtained, for example, by site-directed
10 mutagenesis or by direct synthesis.

By "SNP" is understood any natural variation of a base in a nucleotide sequence. A SNP, on a nucleotide sequence, can be coding, silent or non-coding.

A coding SNP is a polymorphism included in the coding sequence of a nucleotide sequence that involves a modification of an amino acid in the sequence of amino acids
15 encoded by this nucleotide sequence. In this case, the term SNP applies equally, by extension, to a mutation in an amino acid sequence.

A silent SNP is a polymorphism included in the coding sequence of a nucleotide sequence that does not involve a modification of an amino acid in the amino acid sequence encoded by this nucleotide sequence.

20 A non-coding SNP is a polymorphism included in the non-coding sequence of a nucleotide sequence. This polymorphism can notably be found in an intron, a splicing zone, a transcription promoter or a site enhancer sequence.

By "functional SNP" is understood a SNP, such as previously defined, which is included in a nucleotide sequence or an amino acid sequence, having a functionality.

25 By "functionality" is understood the biological activity of a polypeptide or of a polynucleotide.

The functionality of a polypeptide or of a polynucleotide according to the invention can consist in a conservation, an augmentation, a reduction or a suppression of the biological activity of the polypeptide encoded by the nucleotide sequence of the wild-type reference
30 gene or of this latter nucleotide sequence.

The functionality of a polypeptide or of a polynucleotide according to the invention can equally consist in a change in the nature of the biological activity of the polypeptide

encoded by the nucleotide sequence of the reference wild-type gene or of this latter nucleotide sequence.

The biological activity can, notably, be linked to the affinity or to the absence of affinity of a polypeptide according to the invention with a receptor.

5

Polynucleotide

The present invention has for its first object an isolated polynucleotide comprising:

- a) a nucleotide sequence having at least 80 % identity, preferably at least 90 % identity, more preferably at least 95 % identity and still more preferably at least 99 % identity with the sequence SEQ ID NO. 1 or its coding sequence (from nucleotide 670 to nucleotide 1239), it being understood that this nucleotide sequence comprises at least one of the following coding SNPs c794g, c973a, g1011c, t1049a, t1155a, a1204g or
- b) a nucleotide sequence complementary to a nucleotide sequence under a).

10

15

It is understood, in the sense of the present invention, that the numbering corresponds to the positioning of the SNPs in the nucleotide sequence SEQ ID NO. 1.

The present invention relates equally to an isolated polynucleotide comprising:

- a) a nucleotide sequence SEQ ID NO. 1 or its coding sequence, it being understood that each of these sequences comprises at least one of the following coding SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, or
- b) a nucleotide sequence complementary to a nucleotide sequence under a).

20

Preferably, the polynucleotide of the invention consists of the sequence SEQ ID NO. 1 or its coding sequence, it being understood that each of these sequences comprises at least one of the following coding SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g.

According to the invention, the polynucleotide previously defined comprises a single coding SNP selected from the group consisting of: c794g, c973a, g1011c, t1049a, t1155a, and a1204g.

25

A polynucleotide such as previously defined can equally include at least one of the following non-coding SNPs: t1265c, t1277c.

The present invention equally has for its object an isolated polynucleotide comprising or consisting of:

30

- a) a nucleotide sequence SEQ ID NO. 1 or its coding sequence, it being understood that each of these sequences comprises at least one of the following non coding SNPs: t1265c, t1277c, or

b) a nucleotide sequence complementary to a nucleotide sequence under a).

The present invention also concerns an isolated polynucleotide consisting of a part of:

a) a nucleotide sequence SEQ ID NO. 1 or its coding sequence, it being understood that each of these sequences comprises at least one of the following SNPs: c794g, c973a,
5 g1011c, t1049a, t1155a, a1204g, t1265c, t1277c, or

b) a nucleotide sequence complementary to a nucleotide sequence under a).

said isolated polynucleotide being composed of at least 10 nucleotides.

Preferably, the isolated polynucleotide as defined above is composed of 10 to 40 nucleotides.

10 The present invention also has for its object an isolated polynucleotide coding for a polypeptide comprising:

a) the amino acid sequence SEQ ID NO. 2, or

b) the amino acid sequence comprising the amino acids included between positions 24 and 189 in the sequence of amino acids SEQ ID NO. 2,

15 it being understood that each of the amino acid sequences under a) and b) comprises at least one of the following coding SNPs: A42G, Q102K, Q114H, V127D, C162stop, K179E.

It is understood, in the sense of the present invention, that the numbering corresponding to the positioning of the A42G, Q102K, Q114H, V127D, C162stop, K179E
20 SNPs is relative to the numbering of the amino acid sequence SEQ ID NO. 2.

According to a preferred object of the invention, the previously defined polypeptide comprises a single coding SNP such as defined above.

Preferably a polynucleotide according to the invention is composed of a DNA or RNA molecule.

25 A polynucleotide according to the invention can be obtained by standard DNA or RNA synthetic methods.

A polynucleotide according to the invention can equally be obtained by site-directed mutagenesis starting from the nucleotide sequence of the IFN α -21 gene by modifying the wild-type nucleotide by the mutated nucleotide for each SNP on the nucleotide sequence
30 SEQ ID NO. 1.

For example, a polynucleotide according to the invention, comprising a SNP c794g can be obtained by site-directed mutagenesis starting from the nucleotide sequence of the

IFN α -21 gene by modifying the nucleotide cytosine (c) by the nucleotide guanine (g) at position 794 on the nucleotide sequence SEQ ID NO. 1.

The processes of site-directed mutagenesis that can be implemented in this way are well known to a person skilled in the art. The publication of TA Kunkel in 1985 in "Proc. Natl. Acad. Sci. USA" 82:488 can notably be mentioned.

An isolated polynucleotide can equally include, for example, nucleotide sequences coding for pre-, pro- or pre-pro-protein amino acid sequences or marker amino acid sequences, such as hexa-histidine peptide.

A polynucleotide of the invention can equally be associated with nucleotide sequences coding for other proteins or protein fragments in order to obtain fusion proteins or other purification products.

A polynucleotide according to the invention can equally include nucleotide sequences such as the 5' and/or 3' non-coding sequences, such as, for example, transcribed or non-transcribed sequences, translated or non-translated sequences, splicing signal sequences, polyadenylated sequences, ribosome binding sequences or even sequences which stabilize mRNA.

A nucleotide sequence complementary to the nucleotide or polynucleotide sequence is defined as one that can hybridize with this nucleotide sequence, under stringent conditions.

"Stringent hybridization conditions" is generally but not necessarily understood as the chemical conditions that permit a hybridization when the nucleotide sequences have an identity of at least 80 %, preferably greater than or equal to 90 %, still more preferably greater than or equal to 95 % and most preferably greater than or equal to 97 %.

The stringent conditions can be obtained according to methods well known to a person skilled in the art and, for example, by an incubation of the polynucleotides, at 42° C, in a solution comprising 50 % formamide, 5xSSC (150 mM of NaCl, 15 mM of trisodium citrate), 50 mM of sodium phosphate (pH = 7.6), 5x Denhardt Solution, 10 % dextran sulfate and 20 μ g denatured salmon sperm DNA, followed by washing the filters at 0.1x SSC, at 65° C.

Within the scope of the invention, when the stringent hybridization conditions permit hybridization of the nucleotide sequences having an identity equal to 100 %, the nucleotide sequence is considered to be strictly complementary to the nucleotide sequence such as described under a).

It is understood within the meaning of the present invention that the nucleotide sequence complementary to a nucleotide sequence comprises at least one anti-sense SNP according to the invention.

Thus, for example, if the nucleotide sequence comprises the SNP c794g, its complementary nucleotide sequence comprises the cytosine (c) nucleotide at the equivalent of position 794.

Identification, hybridization and/or amplification of a polynucleotide comprising a SNP.

The present invention also has for its object the use of all or part of:

- 10 a) a polynucleotide having 80 to 100 % identity (preferably at least 90 % identity, more preferably 95 % identity and particularly 100 % identity) with the nucleotide sequence SEQ ID NO. 1, and/or
- b) a polynucleotide according to the invention comprising at least one SNP in order to identify, hybridize and/or amplify all or part of a polynucleotide having 80 to 15 100 % identity (preferably at least 90 % identity, more preferably 95 % identity and particularly 100 % identity) with the nucleotide sequence SEQ ID NO. 1 or if necessary its coding sequence (of the nucleotide 670 to the nucleotide 1239),
- it being understood that each one of these sequences comprises at least one of the following SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c.

20

Genotyping and determination of the frequency of a SNP

The present invention equally has for its object the use of all or part of:

- 25 a) a polynucleotide having 80 to 100 % identity (preferably at least 90 % identity, more preferably 95 % identity and particularly 100 % identity) with the nucleotide sequence SEQ ID NO. 1, and/or
- b) a polynucleotide according to the invention comprising at least one SNP for the genotyping of all or part of a polynucleotide having 80 to 100 % identity (preferably at least 90 % identity, more preferably 95 % identity and particularly 100 % identity) with the nucleotide sequence SEQ ID NO. 1 or if necessary its coding sequence 30 (from nucleotide 670 to nucleotide 1239),
- it being understood that each one of these sequences comprises at least one of the following SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c.

According to the invention, the genotyping may be carried out on an individual or a

population of individuals.

Within the meaning of the invention, genotyping is defined as a process for the determination of the genotype of an individual or of a population of individuals. Genotype consists of the alleles present at one or more specific loci.

5 "Population of individuals" is understood as a group of individuals selected in random or non-random fashion. These individuals can be humans, animals, microorganisms or plants.

Usually, the group of individuals comprises at least 10 persons, preferably from 100 to 300 persons.

10 The individuals can be selected according to their ethnicity or according to their phenotype, notably those who are affected by the following disorders and/or diseases: carcinomas, melanomas, lymphomas, leukemias and cancers of the liver, neck, head and kidneys, cardiovascular diseases, metabolic diseases such as those that are not connected with the immune system like, for example, obesity, infectious diseases in particular viral infections like hepatitis B and C and AIDS, pneumonias, ulcerative colitis, diseases of the central nervous
15 system like, for example, Alzheimer's disease, schizophrenia and depression, the rejection of tissue or organ grafts, healing of wounds, anemia in dialyzed patients, allergies, asthma, multiple sclerosis, osteoporosis, psoriasis, rheumatoid arthritis, Crohn's disease, autoimmune diseases and disorders, gastrointestinal disorders or even disorders connected with chemotherapy treatments.

20 A functional SNP according to the invention is preferably genotyped in a population of individuals.

Multiple technologies exist which can be implemented in order to genotype SNPs (see notably Kwok Pharmacogenomics, 2000, vol 1, pp 95-100. "High-throughput genotyping assay approaches"). These technologies are based on one of the four following principles:
25 allele specific oligonucleotide hybridization, oligonucleotide elongation by dideoxynucleotides optionally in the presence of deoxynucleotides, ligation of allele specific oligonucleotides or cleavage of allele specific oligonucleotides. Each one of these technologies can be coupled to a detection system such as measurement of direct or polarized fluorescence, or mass spectrometry.

30 Genotyping can notably be carried out by minisequencing with hot ddNTPs (2 different ddNTPs labeled by different fluorophores) and cold ddNTPs (2 different non labeled ddNTPs), in connection with a polarized fluorescence scanner. The minisequencing protocol with reading of polarized fluorescence (FP-TDI Technology or Fluorescence Polarization

Template-direct Dye-Terminator Incorporation) is well known to a person skilled in the art.

It can be carried out on a product obtained after amplification by polymerase chain reaction (PCR) of the DNA of each individual. This PCR product is selected to cover the polynucleotide genic region containing the studied SNP. After the last step in the PCR thermocycler, the plate is then placed on a polarized fluorescence scanner for a reading of the labeled bases by using fluorophore specific excitation and emission filters. The intensity values of the labeled bases are reported on a graph.

For the PCR amplification, in the case of a SNP of the invention, the sense and antisense primers, respectively, can easily be selected by a person skilled in the art according to the position of the SNPs of the invention.

For example, the sense and antisense nucleotide sequences for the PCR amplification primers can be, respectively:

SEQ ID NO. 3: Sense primer: GGTTC AAGGTTACCCATCTC

SEQ ID NO. 4: Antisense primer: TTTGAAATGGCAGAAGTCAT

The nucleotide sequences permit amplification of a fragment having a length of 696 nucleotides, from nucleotide 620 to nucleotide 1315 in the nucleotide sequence SEQ ID NO. 1.

A statistical analysis of the frequency of each allele (allelic frequency) encoded by the gene comprising the SNP in the population of individuals is then achieved, which permits determination of the importance of their impact and their distribution in the different sub-groups and notably, if necessary, the diverse ethnic groups that constitute this population of individuals.

The genotyping data are analyzed in order to estimate the distribution frequency of the different alleles observed in the studied populations. The calculations of the allelic frequencies can be carried out with the help of software such as SAS-suite® (SAS) or SPLUS® (MathSoft). The comparison of the allelic distributions of a SNP of the invention across different ethnic groups of the population of individuals can be carried out by means of the software ARLEQUIN® and SAS-suite®.

SNPs of the invention as genetic markers.

Whereas SNPs modifying functional sequences of genes (e.g. promoter, splicing sites, coding region) are likely to be directly related to disease susceptibility or resistance, all SNPs (functional or not) may provide valuable markers for the identification of one or several

genes involved in these disease states and, consequently, may be indirectly related to these disease states (See Cargill et al. (1999). Nature Genetics 22:231-238; Riley et al. (2000). Pharmacogenomics 1:39-47; Roberts L. (2000). Science 287: 1898-1899).

Thus, the present invention also concerns a databank comprising at least one of the following SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c, in a polynucleotide of the IFN α -21 gene.

It is well understood that said SNPs are numbered in accordance with the nucleotide sequence SEQ ID NO. 1.

This databank may be analyzed for determining statistically relevant associations between:

(i) at least one of the following SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c, in a polynucleotide of the IFN α -21 gene, and

(ii) a disease or a resistance to a disease.

The present invention also concerns the use of at least one of the following SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c, in a polynucleotide of the IFN α -21 gene, for developing diagnostic/prognostic kits for a disease or a resistance to a disease.

A SNP of the invention such as defined above may be directly or indirectly associated to a disease or a resistance to a disease.

Preferably, these diseases may be those which are defined as mentioned above.

Expression vector and host cells.

The present invention also has for its object a recombinant vector comprising at least one polynucleotide according to the invention.

Numerous expression systems can be used, including without limitation chromosomes, episomes, and derived viruses. More particularly, the recombinant vectors used can be derived from bacterial plasmids, transposons, yeast episomes, insertion elements, yeast chromosome elements, viruses such as baculovirus, papilloma viruses such as SV40, vaccinia viruses, adenoviruses, fox pox viruses, pseudorabies viruses, retroviruses.

These recombinant vectors can equally be cosmid or phagemid derivatives. The nucleotide sequence can be inserted in the recombinant expression vector by methods well known to a person skilled in the art such as, for example, those that are described in

MOLECULAR CLONING: A LABORATORY MANUAL, Sambrook *et al.*, 4th Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001.

The recombinant vector can include nucleotide sequences that control the regulation of the polynucleotide expression as well as nucleotide sequences permitting the expression and the transcription of a polynucleotide of the invention and the translation of a polypeptide of the invention, these sequences being selected according to the host cells that are used.

Thus, for example, an appropriate secretion signal can be integrated in the recombinant vector so that the polypeptide, encoded by the polynucleotide of the invention, will be directed towards the lumen of the endoplasmic reticulum, towards the periplasmic space, on the membrane or towards the extracellular environment.

The present invention also has for its object a host cell comprising a recombinant vector according to the invention.

The introduction of the recombinant vector in a host cell can be carried out according to methods that are well known to a person skilled in the art such as those described in BASIC METHODS IN MOLECULAR BIOLOGY, Davis *et al.*, 2nd ed., McGraw-Hill Professional Publishing, 1995, and MOLECULAR CLONING: A LABORATORY MANUAL, *supra*, such as transfection by calcium phosphate, transfection by DEAE dextran, transfection, microinjection, transfection by cationic lipids, electroporation, transduction or infection.

The host cell can be, for example, bacterial cells such as cells of streptococci, staphylococci, *E. coli* or *Bacillus subtilis*, cells of fungi such as yeast cells and cells of *Aspergillus*, *Streptomyces*, insect cells such as cells of *Drosophila* S2 and of *Spodoptera* Sf9, animal cells, such as CHO, COS, HeLa, C127, BHK, HEK 293 cells and human cells of the subject to treat or even plant cells.

The host cells can be used, for example, to express a polypeptide of the invention or as active product in pharmaceutical compositions, as will be seen hereinafter.

Polypeptide.

The present invention also has for its object an isolated polypeptide comprising an amino acid sequence having at least 80 % identity, preferably at least 90 % identity, more preferably at least 95 % identity and still more preferably at least 99 % identity with:

a) the amino acid sequence SEQ ID NO. 2 or with

b) the amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2,

it being understood that each of the amino acid sequences under a) and b) contains at least one of the following coding SNPs: A42G, Q102K, Q114H, V127D, C162stop, K179E.

5 The polypeptide of the invention can equally comprise:

a) the amino acid sequence SEQ ID NO. 2, or

b) the amino acid sequence containing the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2,

it being understood that each of the amino acid sequences under a) and b) contains at least

10 one of the following coding SNPs: A42G, Q102K, Q114H, V127D, C162stop, K179E.

 The polypeptide of the invention can more particularly consist of:

a) the amino acid sequence SEQ ID NO. 2, or

b) the amino acid sequence containing the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2,

15 it being understood that each one of the amino acid sequences under a) and b) contains at least one of the following coding SNPs: A42G, Q102K, Q114H, V127D, C162stop, K179E.

 Preferably, a polypeptide according to the invention contains a single coding SNP selected from the group consisting of: A42G, Q102K, Q114H, V127D, C162stop, and K179E.

20 The present invention equally has for its object a process for the preparation of the above-described polypeptide, in which a previously defined host cell is cultivated in a culture medium and said polypeptide is isolated from the culture medium.

 The polypeptide can be purified starting from the host cells' culture medium, according to methods well known to a person skilled in the art such as precipitation with the
25 help of chaotropic agents such as salts, in particular ammonium sulfate, ethanol acetone or trichloroacetic acid, acid extraction; ion exchange chromatography; phosphocellulose chromatography; hydrophobic interaction chromatography; affinity chromatography; hydroxyapatite chromatography or exclusion chromatographies.

 "Culture medium" is understood as the medium in which the polypeptide of the
30 invention is isolated or purified. This medium can be composed of the extracellular medium and/or the cellular lysate. Techniques well known to a person skilled in the art equally permit the latter to give back an active conformation to the polypeptide, if the conformation of said polypeptide was altered during the isolation or the purification.

Antibodies.

The present invention also has for its object a process for obtaining an immunospecific antibody.

5 "Antibody" is understood as the monoclonal, polyclonal, chimeric, simple chain, humanized antibodies as well as the Fab fragments, including Fab or immunoglobulin expression library products.

An immunospecific antibody can be obtained by immunization of an animal with a polypeptide according to the invention.

10 The invention also relates to an immunospecific antibody for a polypeptide according to the invention, such as defined previously.

A polypeptide according to the invention, one of its fragments, an analog, one of its variants or a cell expressing this polypeptide can also be used to produce immunospecific antibodies.

15 The term "immunospecific" means that the antibody possesses a better affinity for the polypeptide of the invention than for other polypeptides known in the prior art.

The immunospecific antibodies can be obtained by administration of a polypeptide of the invention, of one of its fragments, of an analog or of an epitopic fragment or of a cell expressing this polynucleotide in a mammal, preferably non human, according to methods
20 well known to a person skilled in the art.

For the preparation of monoclonal antibodies, typical methods for antibody production can be used, starting from cell lines, such as the hybridoma technique (Kohler *et al.*, Nature (1975) 256: 495-497), the trioma technique, the human B cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4: 72) and the EBV hybridoma
25 technique (Cole *et al.*, "The EBV-hybridoma technique and its application to human lung cancer," in Monoclonal Antibodies and Cancer Therapy (Vol. 27, UCLA Symposia on Molecular and Cellular Biology, New Series) (eds. R.A. Reisfeld and S.Sell), pp. 77-96, Alan R. Liss, Inc. N.Y., 1985, pp. 77-96).

The techniques of single chain antibody production such as described, for example, in
30 US Patent No. 4,946, 778 can equally be used.

Transgenic animals such as mice, for example, can equally be used to produce humanized antibodies.

Agents interacting with the polypeptide of the invention.

The present invention equally has for its object a process for the identification of an agent activating or inhibiting a polypeptide according to the invention, comprising:

- 5 a) the preparation of a recombinant vector comprising a polynucleotide according to the invention containing at least one coding SNP,
- b) the preparation of host cells comprising a recombinant vector according to a),
- c) the contacting of host cells according to b) with an agent to be tested, and
- d) the determination of the activating or inhibiting effect generated by the agent to test.

10 A polypeptide according to the invention can also be employed for a process for screening compounds that interact with it.

These compounds can be activating (agonists) or inhibiting (antagonists) agents of intrinsic activity of a polypeptide according to the invention. These compounds can equally be ligands or substrates of a polypeptide of the invention. See Coligan et al., Current Protocols in Immunology 1 (2), Chapter 5 (1991).

15 In general, in order to implement such a process, it is first desirable to produce appropriate host cells that express a polypeptide according to the invention. Such cells can be, for example, cells of mammals, yeasts, insects such as *Drosophila* or bacteria such as *E. coli*.

These cells or membrane extracts of these cells are then put in the presence of compounds to be tested.

20 The binding capacity of the compounds to be tested with the polypeptide of the invention can then be observed, as well as the inhibition or the activation of the functional response.

Step d) of the above process can be implemented by using an agent to be tested that is directly or indirectly labeled. It can also include a competition test, by using a labeled or non-labeled agent and a labeled competitor agent.

25 It can equally be determined if an agent to be tested generates an activation or inhibition signal on cells expressing the polypeptide of the invention by using detection means appropriately chosen according to the signal to be detected.

30 Such activating or inhibiting agents can be polynucleotides, and in certain cases oligonucleotides or polypeptides, such as proteins or antibodies, for example.

The present invention also has for its object a process for the identification of an agent activated or inhibited by a polypeptide according to the invention, comprising:

- a) the preparation of a recombinant vector comprising a polynucleotide according to the

invention containing at least one coding SNP,

b) the preparation of host cells comprising a recombinant vector according to a),

c) placing host cells according to b) in the presence of an agent to be tested, and

d) the determination of the activating or inhibiting effect generated by the polypeptide on the agent to be tested.

An agent activated or inhibited by the polypeptide of the invention is an agent that responds, respectively, by an activation or an inhibition in the presence of this polypeptide. The agents, activated or inhibited directly or indirectly by the polypeptide of the invention, can consist of polypeptides such as, for example, membranal or nuclear receptors, kinases and more preferably tyrosine kinases, transcription factor or polynucleotides.

Detection of diseases.

The present invention also has for object a process for analyzing the biological characteristics of a polynucleotide according to the invention and/or of a polypeptide according to the invention in a subject, comprising at least one of the following:

a) Determining the presence or the absence of a polynucleotide according to the invention in the genome of a subject;

b) Determining the level of expression of a polynucleotide according to the invention in a subject;

c) Determining the presence or the absence of a polypeptide according to the invention in a subject;

d) Determining the concentration of a polypeptide according to the invention in a subject; and/or

e) Determining the functionality of a polypeptide according to the invention in a subject.

These biological characteristics may be analyzed in a subject or in a sample from a subject.

These biological characteristics may permit to carry out a genetic diagnosis and to determine whether a subject is affected or at risk of being affected or, to the contrary, presents a partial resistance to the development of a disease, an indisposition or a disorder linked to the presence of a polynucleotide according to the invention and/or a polypeptide according to the invention.

These diseases can be disorders and/or human diseases, such as cancers and tumors, infectious diseases, venereal diseases, immunologically related diseases and/or autoimmune

diseases and disorders, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments.

Said cancers and tumors include carcinomas comprising metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and
5 chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising Kaposi's sarcoma in the case of AIDS.

Said infectious diseases include viral infections comprising chronic hepatitis B and C
10 and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.

Said immunologically and auto-immunologically related diseases may include the rejection of tissue or organ grafts, allergies, asthma, psoriasis, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis.

Said metabolic diseases may include such non-immune associated diseases as obesity.
15 Said diseases of the central nervous system may include Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

Said diseases and disorders may also include healing of wounds, anemia in dialyzed patient, and osteoporosis.

This process also permits genetic diagnosis of a disease or of a resistance to a disease
20 linked to the presence, in a subject, of the mutant allele encoded by a SNP according to the invention.

Preferably, in step a), the presence or absence of a polynucleotide, containing at least one coding SNP such as previously defined, is going to be detected.

The detection of the polynucleotide may be carried out starting from biological samples
25 from the subject to be studied, such as cells, blood, urine, saliva, or starting from a biopsy or an autopsy of the subject to be studied. The genomic DNA may be used for the detection directly or after a PCR amplification, for example. RNA or cDNA can equally be used in a similar fashion.

It is then possible to compare the nucleotide sequence of a polynucleotide according to the invention with the nucleotide sequence detected in the genome of the subject.

30 The comparison of the nucleotide sequences can be carried out by sequencing, by DNA hybridization methods, by mobility difference of the DNA fragments on an electrophoresis gel with or without denaturing agents or by melting temperature difference. See Myers et al., Science (1985) 230: 1242. Such modifications in the structure of the

nucleotide sequence at a precise point can equally be revealed by nuclease protection tests, such as RNase and the S1 nuclease or also by chemical cleaving agents. See Cotton et al., Proc. Nat. Acad. Sci. USA (1985) 85: 4397-4401. Oligonucleotide probes comprising a polynucleotide fragment of the invention can equally be used to conduct the screening.

5 Many methods well known to a person skilled in the art can be used to determine the expression of a polynucleotide of the invention and to identify the genetic variability of this polynucleotide (See Chee et al., Science (1996), Vol 274, pp 610-613).

In step b), the level of expression of the polynucleotide may be measured by quantifying the level of RNA encoded by this polynucleotide (and coding for a polypeptide) according to methods well known to a person skilled in the art as, for example, by PCR, RT-PCR, RNase protection, Northern blot, and other hybridization methods.

10 In step c) and d) the presence or the absence as well as the concentration of a polypeptide according to the invention in a subject or a sample from a subject may be carried out by well known methods such as, for example, by radioimmunoassay, competitive binding tests, Western blot and ELISA tests.

Consecutively to step d), the determined concentration of the polypeptide according to the invention can be compared with the natural wild-type protein concentration usually found in a subject.

20 A person skilled in the art can identify the threshold above or below which appears the sensitivity or, to the contrary, the resistance to the disease, the indisposition or the disorder evoked above, with the help of prior art publications or by conventional tests or assays, such as those that are previously mentioned.

In step e), the determination of the functionality of a polypeptide according to the invention may be carried out by methods well known to a person skilled in the art as, for example, by in vitro tests such as above mentioned or by an use of host cells expressing said polypeptide.

Therapeutic compounds and treatments of diseases.

30 The present invention also has for its object a therapeutic compound containing, by way of active agent, a polypeptide according to the invention.

The invention also relates to the use of a polypeptide according to the invention, for the manufacture of a therapeutic compound intended for the prevention or the treatment of different human disorders and/or diseases. These diseases can be disorders and/or human diseases, such

as cancers and tumors, infectious diseases, venereal diseases, immunologically related diseases and/or autoimmune diseases and disorders, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments.

Said cancers and tumors include carcinomas comprising metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising Kaposi's sarcoma in the case of AIDS.

Said infectious diseases include viral infections comprising chronic hepatitis B and C and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.

Said immunologically and auto-immunologically related diseases may include the rejection of tissue or organ grafts, allergies, asthma, psoriasis, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis.

Said metabolic diseases may include such non-immune associated diseases as obesity.

Said diseases of the central nervous system may include Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

Said diseases and disorders may also include healing of wounds, anemia in dialyzed patient, and osteoporosis.

Preferably, a polypeptide according to the invention can also be used for the manufacture of a therapeutic compound intended for the prevention or the treatment of different human disorders and/or diseases, such as certain viral infections such as chronic hepatitis B and C, leukemias such as hairy-cell leukemia and chronic myeloid leukemia, multiple myelomas, follicular lymphomas, carcinoid tumors, malignant melanomas, metastasized renal carcinomas, Alzheimer's disease, Parkinson's disease, as well as tumors that appear following an immune deficiency, such as Kaposi's sarcoma in the case of AIDS, and genital warts or venereal diseases.

Certain of the compounds permitting to obtain the polypeptide according to the invention as well as the compounds obtained or identified by or from this polypeptide can likewise be used for the therapeutic treatment of the human body, i.e. as a therapeutic compound.

This is why the present invention also has for an object a medicament containing, by way of active agent, a polynucleotide according to the invention containing at least one

previously defined coding SNP, a previously defined recombinant vector, a previously defined host cell, and/or a previously defined antibody.

The invention also relates to the use of a polynucleotide according to the invention containing at least one previously defined coding SNP, a previously defined recombinant vector,
5 a previously defined host cell, and/or a previously defined antibody for the manufacture of a medicament intended for the prevention or the treatment of different human disorders and/or diseases. These diseases can be disorders and/or human diseases, such as cancers and tumors, infectious diseases, venereal diseases, immunologically related diseases and/or autoimmune diseases and disorders, cardiovascular diseases, metabolic diseases, central nervous system
10 diseases, and disorders connected with chemotherapy treatments.

Said cancers and tumors include carcinomas comprising metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas,
15 carcinoid tumors and tumors that appear following an immune deficiency comprising Kaposi's sarcoma in the case of AIDS.

Said infectious diseases include viral infections comprising chronic hepatitis B and C and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.

Said immunologically and auto-immunologically related diseases may include the
20 rejection of tissue or organ grafts, allergies, asthma, psoriasis, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis.

Said metabolic diseases may include such non-immune associated diseases as obesity.

Said diseases of the central nervous system may include Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

25 Said diseases and disorders may also include healing of wounds, anemia in dialyzed patient, and osteoporosis.

Preferably, the invention concerns the use of a polynucleotide according to the invention containing at least one previously defined SNP, a previously defined recombinant vector, a previously defined host cell, and/or a previously defined antibody, for the
30 manufacture of a medicament intended for the prevention or the treatment of different human disorders and/or diseases, such as certain viral infections such as chronic hepatitis B and C, leukemias such as hairy-cell leukemia and chronic myeloid leukemia, multiple myelomas, follicular lymphomas, carcinoid tumors, malignant melanomas, metastasized renal

carcinomas, Alzheimer's disease, Parkinson's disease, as well as tumors that appear following an immune deficiency, such as Kaposi's sarcoma in the case of AIDS, and genital warts or venereal diseases.

5 The dosage of a polypeptide and of the other compounds of the invention, useful as active agent, depends on the choice of the compound, the therapeutic indication, the mode of administration, the nature of the formulation, the nature of the subject and the judgment of the doctor.

When it is used as active agent, a polypeptide according to the invention is generally administered at doses ranging between 1 and 100 µg/kg of the subject.

10 The invention also has as an object a pharmaceutical composition that contains, as active agent, at least one above-mentioned compound such as a polypeptide according to the invention, a polynucleotide according to the invention containing at least one previously defined SNP, a previously defined recombinant vector, a previously defined host cell, and/or a previously defined antibody, as well as a pharmaceutically acceptable excipient.

15 In these pharmaceutical compositions, the active agent is advantageously present at physiologically effective doses.

These pharmaceutical compositions can be, for example, solids or liquids and be present in pharmaceutical forms currently used in human medicine such as, for example, simple or coated tablets, gelcaps, granules, caramels, suppositories and preferably injectable
20 preparations and powders for injectables. These pharmaceutical forms can be prepared according to usual methods.

The active agent(s) can be incorporated into excipients usually employed in pharmaceutical compositions such as talc, Arabic gum, lactose, starch, dextrose, glycerol, ethanol, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances
25 of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives.

The active agent(s) according to the invention can be employed alone or in combination with other compounds such as therapeutic compounds such as other cytokines such as interleukins or interferons, for example.

30 The different formulations of the pharmaceutical compositions are adapted according to the mode of administration.

The pharmaceutical compositions can be administered by different routes of administration known to a person skilled in the art.

The invention equally has for an object a diagnostic composition that contains, as active agent, at least one above-mentioned compound such as a polypeptide according to the invention, all or part of a polynucleotide according to the invention, a previously defined recombinant vector, a previously defined host cell, and/or a previously defined antibody, as well as a suitable pharmaceutically acceptable excipient.

This diagnostic composition may contain, for example, an appropriate excipient like those generally used in the diagnostic composition such as buffers and preservatives.

The present invention equally has as an object the use:

- a) of a therapeutically effective quantity of a polypeptide according to the invention, and/or
 - 10 b) of a polynucleotide according to the invention, and/or
 - c) of a host cell from the subject to be treated, previously defined,
- to prepare a therapeutic compound intended to increase the expression or the activity, in a subject, of a polypeptide according to the invention.

Thus, to treat a subject who needs an increase in the expression or in the activity of a polypeptide of the invention, several methods are possible.

It is possible to administer to the subject a therapeutically effective quantity of a polypeptide of the invention, with a pharmaceutically acceptable excipient.

It is likewise possible to increase the endogenous production of a polypeptide of the invention by administration to the subject of a polynucleotide according to the invention. For example, this polynucleotide can be inserted in a retroviral expression vector. Such a vector can be isolated starting from cells having been infected by a retroviral plasmid vector containing RNA encoding for the polypeptide of the invention, in such a fashion that the transduced cells produce infectious viral particles containing the gene of interest. See Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, Chapter 20, in Human Molecular Genetics, Strachan and Read, BIOS Scientific Publishers Ltd (1996).

In accordance with the invention, a polynucleotide containing at least one coding SNP such as previously defined will be preferably used.

It is equally possible to administer to the subject host cells belonging to him, these host cells having been preliminarily taken and modified so as to express the polypeptide of the invention, as previously described.

The present invention equally relates to the use:

- a) of a therapeutically effective quantity of a previously defined immunospecific antibody, and/or

b) of a polynucleotide permitting inhibition of the expression of a polynucleotide according to the invention,

in order to prepare a therapeutic compound intended to reduce the expression or the activity, in a subject, of a polypeptide according to the invention.

5 Thus, it is possible to administer to the subject a therapeutically effective quantity of an inhibiting agent and/or of an antibody such as previously defined, possibly in combination, with a pharmaceutically acceptable excipient.

It is equally possible to reduce the endogenous production of a polypeptide of the invention by administration to the subject of a complementary polynucleotide according to
10 the invention permitting inhibition of the expression of a polynucleotide of the invention.

Preferably, a complementary polynucleotide containing at least one coding SNP such as previously defined can be used.

The present invention concerns also the use of a IFN α -21 protein for the preparation of a medicament for the prevention or the treatment of a patient having a disorder or a disease
15 caused by a IFN α -21 variant linked to the presence in the genome of said patient of a nucleotide sequence having at least 95% identity (preferably, 97% identity, more preferably 99% identity and particularly 100% identity) with the nucleotide sequence SEQ ID NO. 1, provided that said nucleotide sequence comprises one of the following SNPs: c794g, c973a, g1011c, t1049a, t1155a, a1204g, t1265c, t1277c.

20 Preferably, said medicament is used for the prevention or the treatment of one of the diseases selected from the group consisting of cancers and tumors, infectious diseases, venereal diseases, immunologically related diseases and/or autoimmune diseases and disorders, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments.

25 Said cancers and tumors include carcinomas comprising metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising
30 Kaposi's sarcoma in the case of AIDS.

Said infectious diseases include viral infections comprising chronic hepatitis B and C and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.

Said immunologically and auto-immunologically related diseases may include the

rejection of tissue or organ grafts, allergies, asthma, psoriasis, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis.

Said metabolic diseases may include such non-immune associated diseases as obesity.

Said diseases of the central nervous system may include Alzheimer's disease,
5 Parkinson's disease, schizophrenia and depression.

Said diseases and disorders may also include healing of wounds, anemia in dialyzed patient, and osteoporosis.

Mimetic compounds of an IFN α -21 polypeptide comprising the SNPs of the invention.

10 The present invention also concerns a new compound having a biological activity substantially similar to that of the polypeptide of:

a) amino acid sequence SEQ ID NO. 2, or

b) amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2;

15 provided that said amino acid sequences under a) and b) comprise the SNP K179E.

Said biological activity may be evaluated, for example, by measuring the capacity to stimulate dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative activity on Daudi Burkitt's cell line, cellular antiproliferative activity on TF-1 cell line as
20 described in the experimental part.

As mentioned in the experimental section, the K179E mutated IFN α -21 differs from the wild-type IFN α -2 in the following ways:

▲ K179E mutated IFN α -21 possesses higher capacity to stimulate dendritic cell maturation;

25 ▲ K179E mutated IFN α -21 possesses a higher capacity to stimulate IFN-gamma release by CD4+ or CD8+ T-lymphocytes;

▲ K179E mutated IFN α -21 possesses an antiviral activity in cell culture infected with VSV which is lower than that of wild-type IFN α -2.

As mentioned in the experimental part, K179E mutated IFN α -21 possesses a cellular
30 antiproliferative activity on Daudi Burkitt's cell line which is slightly lower than that of the natural wild- type IFN α -21.

Also as mentioned in the experimental part, the K179E mutated IFN α -21 possesses a cellular antiproliferative activity on TF-1 cell line which is similar to that of wild-type IFN α -

2, and an antiviral activity in EMCV mouse model which is similar to that of wild-type IFN α -2.

A new compound of the invention, such as previously defined, may possess a biological activity substantially similar to that of the K179E mutated IFN α -21.

5 Said compound may also have a biological activity which is even lower or higher, according to the kind of biological activity considered, than that of the K179E mutated IFN α -21.

10 Said compound may be a biochemical compound, such as a polypeptide or a peptide for example, or an organic chemical compound, such as a synthetic peptide-mimetic for example.

The present invention also concerns the use of a polypeptide of the invention containing the K179E SNP, for the identification of a compound such as defined above.

The present invention also concerns a process for the identification of a compound of the invention, comprising the following steps:

- 15 a) Determining the biological activity of the compound to be tested, such as dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative activity on Daudi Burkitt's cell line, for example;
- b) Comparing:
- 20 i) the activity determined in step a) of the compound to be tested, with
- ii) the activity of the polypeptide of amino acid sequence SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2; provided that said amino acid sequences comprise the K179E SNP; and
- 25 c) Determining on the basis of the comparison carried out in step b) whether the compound to be tested has a substantially similar, or lower or higher, activity compared to that of the polypeptide of amino acid sequence SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2; provided that said amino acid sequences comprise the K179E
- 30 SNP.

Preferably, the compound to be tested may be previously identified from synthetic peptide combinatorial libraries, high-throughput screening, or designed by computer-aided drug design so as to have the same three-dimensional structure as that of the polypeptide of

amino acid sequence SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2; provided that said amino acid sequences comprise the K179E SNP.

5 The present invention also concerns a new compound having a biological activity substantially similar to that of the polypeptide of:

a) amino acid sequence SEQ ID NO. 2, or

b) amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2;

10 provided that said amino acid sequences under a) and b) comprise the SNPs Q114H and V127D.

Said biological activity may be evaluated, for example, by measuring the capacity to stimulate dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative
15 activity on Daudi Burkitt's cell line, cellular antiproliferative activity on TF-1 cell line as described in the experimental part.

As mentioned in the experimental section, IFN α -21 containing both SNPs Q114H and V127D (such double mutation shall be referred to hereafter as "Q114H/V127D") differs from the wild-type IFN α -2 in the following ways:

20 Δ the Q114H/V127D mutated IFN α -21 possesses a higher capacity to stimulate IFN-gamma release by CD4+ or CD8+ T-lymphocytes;

Δ the Q114H/V127D mutated IFN α -21 possesses a lower antiviral activity in cell culture infected with VSV;

As mentioned in the experimental part, the Q114H/V127D mutated IFN α -21
25 possesses a cellular antiproliferative activity on Daudi Burkitt's cell line which is lower than that of the natural wild-type IFN α -21.

Also as mentioned in the experimental part, the Q114H/V127D mutated IFN α -21 possesses an antiviral activity in EMCV mouse model which is similar to that of wild-type IFN α -2, a capacity to stimulate IL-10, IL-12 and TNF- α release by monocytes which is
30 similar to that of wild-type IFN α -2, and cellular antiproliferative activity on TF-1 cell line which is similar to that of wild-type IFN α -2.

A new compound of the invention, such as previously defined, may possess a biological activity substantially similar to that of the Q114H/V127D mutated IFN α -21.

Said compound may also have a biological activity which is even lower or higher, according to the kind of biological activity considered, than that of the Q114H/V127D mutated IFN α -21.

5 Said compound may be a biochemical compound, such as a polypeptide or a peptide for example, or an organic chemical compound, such as a synthetic peptide-mimetic for example.

The present invention also concerns the use of a polypeptide of the invention containing the Q114H/V127D SNP, for the identification of a compound such as defined above.

10 The present invention also concerns a process for the identification of a compound of the invention, comprising the following steps:

a) Determining the biological activity, such as dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative activity on Daudi Burkitt's cell line, for
15 example;

b) Comparing:

i) the activity determined in step a) of the compound to be tested, with

ii) the activity of the polypeptide of amino acid sequence SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of
20 the amino acid sequence SEQ ID NO. 2;

provided that said amino acid sequences comprise the Q114H/V127D SNP; and

c) Determining on the basis of the comparison carried out in step b) whether the compound to be tested has a substantially similar, or lower or higher, activity compared to that of the polypeptide of amino acid sequence SEQ ID NO. 2, or of amino acid sequence
25 comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2; provided that said amino acid sequences comprise the Q114H/V127D SNP.

Preferably, the compound to be tested may be previously identified from synthetic peptide combinatorial libraries, high-throughput screening, or designed by computer-aided
30 drug design so as to have the same three-dimensional structure as that of the polypeptide of amino acid sequence SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2; provided that said amino acid sequences comprise the Q114H/V127D SNPs.

The methods to identify and design compounds are well known by a person skilled in the art.

Publications referring to these methods may be, for example:

- Silverman R.B. (1992). "Organic Chemistry of Drug Design and Drug Action".
5 Academic Press, 1st edition (January 15, 1992).

- Anderson S and Chiplin J. (2002). "Structural genomics; shaping the future of drug design" Drug Discov. Today. 7(2):105-107.

- Selick HE, Beresford AP, Tarbit MH. (2002). "The emerging importance of predictive ADME simulation in drug discovery". Drug Discov. Today. 7(2):109-116.

10 - Burbidge R, Trotter M, Buxton B, Holden S. (2001). "Drug design by machine learning: support vector machines for pharmaceutical data analysis". Comput. Chem. 26(1): 5-14.

- Kauvar L.M. (1996). "Peptide mimetic drugs: a comment on progress and prospects" 14(6): 709.

15 The compounds of the invention may be used for the preparation of a medicament intended for the prevention or the treatment of one of the diseases selected from the group consisting of cancers and tumors, infectious diseases, venereal diseases, immunologically related diseases and/or autoimmune diseases and disorders, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments.

20 Said cancers and tumors include carcinomas comprising metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising
25 Kaposi's sarcoma in the case of AIDS.

Said infectious diseases include viral infections comprising chronic hepatitis B and C and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.

Said immunologically and auto-immunologically related diseases may include the rejection of tissue or organ grafts, allergies, asthma, psoriasis, rheumatoid arthritis, multiple
30 sclerosis, Crohn's disease and ulcerative colitis.

Said metabolic diseases may include such non-immune associated diseases as obesity.

Said diseases of the central nervous system may include Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

Said diseases and disorders may also include healing of wounds, anemia in dialyzed patient, and osteoporosis.

The compounds of the invention may be used for the preparation of a medicament intended for the prevention or the treatment of one of the diseases selected from the group consisting of certain viral infections such as chronic hepatitis B and C, leukemias such as hairy-cell leukemia and chronic myeloid leukemia, multiple myelomas, follicular lymphomas, carcinoid tumors, malignant melanomas, metastasized renal carcinomas, Alzheimer's disease, Parkinson's disease, as well as tumors that appear following an immune deficiency, such as Kaposi's sarcoma in the case of AIDS, and genital warts or venereal diseases.

EXPERIMENTAL SECTION

Example 1: Modeling of a protein encoded by a polynucleotide of nucleotide sequence containing SNP c794g, c973a, g1011c, t1049a, t1155a, a1204g and of the protein encoded by the nucleotide sequence of the wild-type reference gene

In a first step the three-dimensional structure of IFN α -21 was constructed starting from that of IFN α -2 whose structure is available in the PDB database (code 1ITF) and by using the software Modeler (MSI, San Diego, CA).

The mature polypeptide fragment was then modified in such a fashion as to reproduce the mutation A19G, Q79K, Q91H, V104D, C139stop, and K156E.

A thousand molecular minimization steps were conducted on this mutated fragment by using the programs AMBER and DISCOVER (MSI: Molecular Simulations Inc.).

Two molecular dynamic calculation runs were then carried out with the same program and the same force fields.

In each case, 50,000 steps were calculated at 300°K, terminated by 300 equilibration steps.

The result of this modeling is visualized on Figures 1, 2, 3, 4, and 5.

Example 2: Genotyping of the SNPs c794g, c973a, g1011c, t1049a, t1155a, a1204g in a population of individuals

The genotyping of SNPs is based on the principle of the minisequencing wherein the product is detected by a reading of polarized fluorescence. The technique consists of a fluorescent minisequencing (FP-TDI Technology or Fluorescence Polarization Template-

direct Dye-terminator Incorporation).

The minisequencing is performed on a product amplified by PCR from genomic DNA of each individual of the population. This PCR product is chosen in such a manner that it covers the genic region containing the SNP to be genotyped. After elimination of the PCR
5 primers that have not been used and the dNTPs that have not been incorporated, the minisequencing is carried out.

The minisequencing consists of lengthening an oligonucleotide primer, placed just upstream of the site of the SNP, by using a polymerase enzyme and fluorolabeled dideoxynucleotides. The product resulting from this lengthening process is directly analyzed
10 by a reading of polarized fluorescence.

All these steps, as well as the reading, are carried out in the same PCR plate.

Thus, the genotyping requires 5 steps:

- 1) Amplification by PCR
- 2) Purification of the PCR product by enzymatic digestion
- 15 3) Elongation of the oligonucleotide primer
- 4) Reading
- 5) Interpretation of the reading

The genotyping steps 1 and 2 are carried out in the same conditions for each of the SNPs c794g, c973a, g1011c, t1049a, t1155a, a1204g. The steps 3, 4 and 5 are specific to each one
20 of these polymorphisms.

1) The PCR amplification of the nucleotide sequence of the IFN α -21 gene is carried out starting from genomic DNA coming from 268 individuals of ethnically diverse origins.

These genomic DNAs were provided by the Coriell Institute in the United States.

25 The 268 individuals are distributed as follows:

Phylogenetic Population	Specific Ethnic Population	Total	%
African American	African American	50	100.0
	<i>Subtotal</i>	50	18.7
Amerind	South American Andes	10	66.7
	South West American Indians	5	33.3
	<i>Subtotal</i>	15	5.6
Caribbean	Caribbean	10	100.0
	<i>Subtotal</i>	10	3.7
European Caucasoid	North American Caucasian	79	79.8
	Iberian	10	10.1
	Italian	10	10.1
	<i>Subtotal</i>	99	36.9
Mexican	Mexican	10	100.0
	<i>Subtotal</i>	10	3.7
Northeast Asian	Chinese	10	50.0
	Japanese	10	50.0
	<i>Subtotal</i>	20	7.5
Non-European Caucasoid	Greek	8	21.6
	Indo-Pakistani	9	24.3
	Middle-Eastern	20	54.1
	<i>Subtotal</i>	37	13.8
Southeast Asian	Pacific Islander	7	41.2
	South Asian	10	58.8
	<i>Subtotal</i>	17	6.3
South American	South American	10	100.0
	<i>Subtotal</i>	10	3.7
<i>Total</i>		268	100

The genomic DNA coming from each one of these individuals constitutes a sample.

For all the SNPs, the PCR amplification is carried out starting from the following
5 primers:

SEQ ID NO. 5: Sense primer: GGTTC AAGGTTACCCATCTC

SEQ ID NO. 6: Antisense primer: TTTGAAATGGCAGAAGTCAT

These nucleotide sequences permit amplification of a fragment of a length of 696 nucleotides, from nucleotide 620 to nucleotide 1315 in the nucleotide sequence SEQ ID NO. 1.

10 For each SNP, the PCR product will serve as a template for the minisequencing

The total reaction volume of the PCR reaction is 5 μ l per sample.

This reaction volume is composed of the reagents indicated in the following table:

Supplier	Reference	Reactant	Initial Conc.	Vol. per tube (μ l)	Final Conc.
Life Technology	Delivered with Taq	Buffer (X)	10	0.5	1
Life Technology	Delivered with Taq	MgSO ₄ (mM)	50	0.2	2
AP Biotech	27-2035-03	dNTPs (mM)	10	0.1	0.2
	On request	Sense Primer (μ M)	10	0.1	0.2
	On request	Antisense Primer (μ M)	10	0.1	0.2
Life Technology	11304-029	Taq platinum	5U/ μ l	0.02	0.1 U/ reaction
		H ₂ O	Qsp 5 μ l	1.98	
		DNA (sample)	2.5 ng/ μ l	2	5 ng/ reaction
		Total volume		5 μ l	

These reagents are distributed in a black PCR plate having 384 wells provided by
 5 ABGene (ref: TF-0384-k). The plate is sealed, centrifuged, then placed in a thermocycler for 384-well plates (Tetrad of MJ Research) and undergoes the following incubation: PCR Cycles: 1 min at 94° C, followed by 36 cycles composed of 3 steps (15 sec. at 94° C, 30 sec. at 56° C, 1 min at 68° C).

2) The PCR amplified product is then purified using two enzymes: Shrimp Alkaline
 10 Phosphatase (SAP) and exonuclease I (Exo I). The first of these enzymes permits the dephosphorylation of the dNTPs which have not been incorporated during the PCR amplification, whereas the second eliminates the single stranded DNA residues, in particular the primers which have not been used during the PCR.

This digestion is done by addition, in each well of the PCR plate, of a reaction
 15 mixture of 5 μ l per sample. This reaction mixture is composed of the following reagents:

Supplier	Reference	Reactant	Initial Conc.	Vol. per tube (μ l)	Final conc.
AP Biotech	E70092X	SAP	1 U/ μ l	0.5	0.5/reaction
AP Biotech	070073Z	Exo I	10 U/ μ l	0.1	1/reaction
AP Biotech	Supplied with SAP	Buffer SAP (X)	10	0.5	1
		H ₂ O	Qsp 5 μ l	3.9	
		PCR product		5 μ l	
		Total vol.		10 μ l	

Once filled, the plate is sealed, centrifuged, then placed in a thermocycler for 384 well plates (Tetrad of MJ Research) and undergoes the following incubation: Digestion SAP-
5 EXO: 45 min at 37° C, 15 min at 80° C.

The elongation or minisequencing step is then carried out on the product of PCR digested by addition of a reaction mixture of 5 µl per prepared sample.

The minisequencing 3) and the reading steps 4) and interpretation of reading 5) are specific to each SNP c794g, c973a, g1011c, t1049a, t1155a, a1204g.

10 All these steps are described hereinafter precisising the specific conditions used for each one of these polymorphisms.

3) Minisequencing

The sequences of the two minisequencing primers necessary for the genotyping were determined in a way to correspond to the sequence of the nucleotides located upstream of the
15 site of a SNP according to the invention. The PCR product that contains the SNP being a double stranded DNA product, the genotyping can therefore be done either on the sense strand or on the antisense strand. The selected primers are manufactured by Life Technologies Inc.

20 The following table indicates, for each SNP, the sequence of the minisequencing primers that have been tested and the optimal condition retained for the genotyping:

SNP	Primers tested	Optimal condition for the genotyping
c794g	SEQ ID NO. 7: Sense: gagggccttgatactcctgg SEQ ID NO. 8: Antisense: gagagattcttcccatttgt	antisense primer + ddGTP-R110 + ddCTP-Tamra
c973a	SEQ ID NO. 9: Sense: actcatctgctacttgggaa SEQ ID NO. 10: Antisense: aaatttttctaggaggctct	antisense primer + dGTP-R110 + ddTTP-Tamra
g1011c	SEQ ID NO. 11: Sense: tttccactgaacttaacca SEQ ID NO. 12: Antisense: gcttcaggtcattcagctg	antisense primer + ddGTP-R110 + ddCTP-Tamra
t1049a	SEQ ID NO. 13: Sense: agcctgcgtgatacaggagg SEQ ID NO. 14: Antisense: ggggagtctcttccacccca	antisense primer + ddATP-R110 + ddTTP-Tamra
t1155a	SEQ ID NO. 15: Sense: gagaagaaatacacgccttg SEQ ID NO. 16: Antisense: gctctgacaacctccaggc	antisense primer + ddATP-R110 + ddTTP-Tamra
a1204g	SEQ ID NO. 17: Sense: tgagatccttctctttatca SEQ ID NO. 18: Antisense: taatcttcttgaaaaattt	sense primer + ddGTP-R110 + ddATP-Tamra

The minisequencing of the SNPs was first validated over 16 samples, then genotyped over the set of the population of individuals composed of 268 individuals and 10 controls.

The elongation or minisequencing step is then carried out as indicated in the following table:

Supplier	Reference	Reactant	Initial conc.	Vol. per tube (μ l)	Final conc.
Own preparation		Elongation Buffer ¹ (X)	5	1	1
Life Technologies	On request	Miniseq Primer (μ M) A or B	10	0.5	1
AP Biotech	27-2051 (61,71,81)-01	ddNTPs ² (μ M) 2 are non labeled	2.5 of each	0.25	0.125 of each
NEN	Nel 472/5 and Nel 492/5	ddNTPs ² (μ M) 2 are labeled with Tamra and R110	2.5 of each	0.25	0.125 of each
AP Biotech	E79000Z	Thermo-sequenase	3.2 U/ μ l	0.125	0.4 U/ reaction
		H ₂ O	Qsp 5 μ l	3.125	
		digested PCR product		10	
		Total volume		15	

¹ The 5X elongation buffer is composed of 250 mM Tris-HCl pH 9, 250 mM KCl, 25 mM NaCl, 10 mM MgCl₂ and 40 % glycerol.

² For the ddNTPs, a mixture of the 4 bases is carried out according to the polymorphism studied. Only the 2 bases of interest (wild-type nucleotide/mutated nucleotide) composing the functional SNP are labeled, either in Tamra, or in R110. For example:

For SNP c973a, the mixture of ddNTPs is composed of:

- 2.5 μ M of ddCTP non labeled,
- 2.5 μ M of ddATP non-labeled,
- 2.5 μ M of ddTTP (1.875 μ M of ddTTP non labeled and 0.625 μ M of ddTTP Tamra labeled),
- 2.5 μ M of ddGTP (1.875 μ M of ddGTP non labeled and 0.625 μ M of ddGTP R110 labeled).

Once filled, the plate is sealed, centrifuged, then placed in a thermocycler for 384-well plates (Tetrad of MJ Research) and undergoes the following incubation: Elongation cycles: 1 min. at 93° C, followed by 35 cycles composed of 2 steps (10 sec. at 93° C, 30 sec. at 55° C).

After the last step in the thermocycler, the plate is directly placed on a polarized fluorescence reader of type Analyst® HT of LJI Biosystems Inc. The plate is read using Criterion Host® software by using two methods. The first permits reading the Tamra labeled base by using emission and excitation filters specific for this fluorophore (excitation 550-10 nm, emission 580-10 nm) and the second permits reading the R110 labeled base by using the excitation and emission filters specific for this fluorophore (excitation 490-10 nm, emission 520-10 nm). In the two cases, a dichroic double mirror (R110/Tamra) is used and the other

reading parameters are:

Z-height: 1.5 mm

Attenuator: out

Integration time: 100,000 μ sec.

5 Raw data units: counts/sec

Switch polarization: by well

Plate settling time: 0 msec

PMT setup: Smart Read (+), sensitivity 2

Dynamic polarizer: emission

10 Static polarizer: S

A file result is thus obtained containing the calculated values of mP (milliPolarization) for the Tamra filter and that for the R110 filter. These mP values are calculated starting from intensity values obtained on the parallel plane (//) and on the perpendicular plane (\perp) according to the following formula:

15
$$MP = 1000(// - g\perp)/(// + g\perp).$$

In this calculation, the value \perp is weighted by a factor g. It is a machine parameter that must be determined experimentally beforehand.

4) and 5) Interpretation of the reading and determination of the genotypes.

The mP values are reported on a graph using Microsoft Inc. Excel software, and/or
20 Allele Caller® software developed by LJI Biosystems Inc.

On the abscissa is indicated the mP value of the Tamra labeled base, on the ordinate is indicated the mP value of the R110 labeled base. A strong mP value indicates that the base labeled with this fluorophore is incorporated and, conversely, a weak mP value reveals the absence of incorporation of this base.

25 Up to three homogenous groups of nucleotide sequences having different genotypes may be obtained.

The use of the Allele Caller® software permits, once the identification of the different groups is carried out, to directly extract the genotype defined for each individual in table form.

Results of the minisequencing for the SNPs c794g, c973a, g1011c, t1049a, t1155a, a1204g

After the completion of the genotyping process, the determination of the genotypes of the individuals of the population of individuals for the SNPs studied here was carried out using the graphs described above.

5 For SNP c794g, the genotype is in theory either homozygote CC, or heterozygote CG, or homozygote GG in the tested individuals. In reality, and as shown below, the homozygote genotype GG is not detected in the population of individuals.

For SNP c973a, the genotype is in theory either homozygote CC, or heterozygote CA, or homozygote AA in the tested individuals. In reality, and as shown below, the homozygote
10 genotype AA is not detected in the population of individuals.

For SNP g1011c, the genotype is in theory either homozygote GG, or heterozygote GC, or homozygote CC in the tested individuals. In reality, and as shown below, the homozygote genotype CC is not detected in the population of individuals.

For SNP t1049a, the genotype is in theory either homozygote TT, or heterozygote TA,
15 or homozygote AA in the tested individuals. In reality, and as shown below, the homozygote genotype AA is not detected in the population of individuals.

For SNP t1155a, the genotype is in theory either homozygote TT, or heterozygote TA, or homozygote AA in the tested individuals. In reality, and as shown below, the homozygote genotype AA is not detected in the population of individuals.

20 For SNP a1204g, the genotype is in theory either homozygote AA, or heterozygote AG, or homozygote GG in the tested individuals. In reality, and as shown below, the homozygote genotype GG is not detected in the population of individuals.

The results of the distribution of the determined genotypes in the population of individuals and the calculation of the different allelic frequencies for the 6 SNPs studied are
25 presented in the following tables:

Phylogenic Population		c794g (A42G)							
		<i>f</i>	(95% CI)	CC	%	CG	%	GG	Total
African American	50	5,0	(0.7, 9.3)	45	90,0	5	10		50
Amerind	15			15	100				15
Caribbean	10			10	100				10
European Caucasoid	99			99	100				99
Mexican	10			10	100				10
Non-European Caucasoid	37			37	100				37
Northeast Asian	20			20	100				20
South American	10	2,9	(0, 8.6)	10	100				10
Southeast Asian	17			16	94,1	1	5,9		17
Total	268	1,1	(0.2, 2.0)	262	97,8	6	2,2		268

Phylogenic Population		c973a (Q102K)							
		<i>f</i>	(95% CI)	CC	%	CA	%	AA	Total
African American	50	1,5	(0, 3.2)	49	100				49
Amerind	15			15	100				15
Caribbean	10			10	100				10
European Caucasoid	99			96	97,0	3	3,0		99
Mexican	10			9	100				9
Non-European Caucasoid	37			36	97,3	1	2,7		37
Northeast Asian	20			20	100				20
South American	10	1,4	(0, 4.0)	10	100				10
Southeast Asian	17			17	100				17
Total	268	0,8	(0, 1.5)	262	98,5	4	1,5		266

Phylogenic Population		g1011c (Q114H)							
		<i>f</i>	(95% CI)	GG	%	GC	%	CC	Total
African American	50	0,5	(0, 1.6)	49	100				49
Amerind	15			15	100				15
Caribbean	10			10	100				10
European Caucasoid	99			92	98,9	1	1,1		93
Mexican	10			10	100				10
Non-European Caucasoid	37			37	100				37
Northeast Asian	20			20	100				20
South American	10	0,2	(0, 0.6)	10	100				10
Southeast Asian	17			17	100				17
Total	268	0,2	(0, 0.6)	260	99,6	1	0,4		261

Phylogenetic Population	Total	t1049a (V127D)							
		f	(95% CI)	TT	%	TA	%	AA	Total
African American	50	1,0	(0, 3.0)	48	98,0	1	2,0		49
Amerind	15			14	100				14
Caribbean	10			10	100				10
European Caucasoid	99			98	100				98
Mexican	10			10	100				10
Non-European Caucasoid	37			37	100				37
Northeast Asian	20			20	100				20
South American	10			10	100				10
Southeast Asian	17			17	100				17
Total	268	0,2	(0, 0.6)	264	99,6	1	0,4		265

Phylogenetic Population	Total	t1155a (C162STOP)							
		f	(95% CI)	TT	%	TA	%	AA	Total
African American	50	1,0	(0, 3.0)	48	98,0	1	2,0		49
Amerind	15			15	100				15
Caribbean	10			9	100				9
European Caucasoid	99	3,6	(1.0, 6.2)	91	92,9	7	7,1		98
Mexican	10			10	100				10
Non-European Caucasoid	37			37	100				37
Northeast Asian	20			20	100				20
South American	10			10	100				10
Southeast Asian	17			17	100				17
Total	268	1,5	(0.5, 2.5)	257	97,0	8	3,0		264

Phylogenetic Population	Total	a1204g (K179E)							
		f	(95% CI)	AA	%	AG	%	GG	Total
African American	50			50	100				50
Amerind	15	3,6	(0, 10.4)	13	92,9	1	7,1		14
Caribbean	10			10	100				10
European Caucasoid	99	1,0	(0, 2.4)	97	98,0	2	2,0		99
Mexican	10	10,0	(0, 23.1)	8	80,0	2	20,0		10
Non-European Caucasoid	37	2,7	(0, 6.4)	35	94,6	2	5,4		37
Northeast Asian	20	17,5	(5.7, 29.3)	13	65,0	7	35,0		20
South American	10	5,0	(0, 14.6)	9	90,0	1	10,0		10
Southeast Asian	17			17	100				17
Total	268	2,8	(1.4, 4.2)	252	94,4	15	5,6		267

In the above table,

- N represents the number of individuals,
- % represents the percentage of individuals in the specific sub-population,
- 5 - the allelic frequency represents the percentage of the mutated allele in the specific sub-population,
- 95 % IC represents the minimal and maximal interval of confidence at 95 %.

It is necessary to specify that for SNP c973a, for example, the allele g read in antisense corresponds to the allele c read in sense, and is related to the presence of a glutamine (Q) at position 102 of the immature IFN α -21 protein sequence and therefore
10 that the allele t read in antisense corresponds to the allele a read in sense corresponding to a lysine (K) for this position in the sequence of the corresponding protein.

By examining these results by phylogenic population, and by SNP, it is observed that:

- 15 - for SNP c794g, the 6 heterozygote individuals CG come from the sub-populations African American and Southeast Asian.
- for SNP c973a, the 4 heterozygote individual CA come from the sub-populations European and non-European Caucasoid.
- for SNP g1011c, the unique heterozygote individual GC comes from the sub-
20 population European Caucasoid.
- for SNP t1049a, the unique heterozygote individual TA comes from the sub-population African American.
- for SNP t1155a, the 8 heterozygote individual TA come from the sub-populations African American and European Caucasoid.
- 25 - for SNP a1204g, the 15 heterozygote individual AG come from the sub-populations Amerind, European and non-European Caucasoid, Mexican, Northeast Asian and South American.

Example 3. Expression of natural wild-type IFN α -21 and A42G, Q102K, Q114H/V127D, K179E mutated IFN α -21 in yeast

a) Cloning of the natural wild-type IFN α -21 and mutated IFN α -21 in the eukaryote expression vector pPicZ α -topo

5 The nucleotide sequences coding for the mature part of the natural wild-type IFN α -21 and A42G, Q102K, Q114H/V127D, K179E mutated IFN α -21 are amplified by PCR using as template genomic DNA from an individual who is heterozygote for the corresponding SNP(s).

The PCR primers permitting such an amplification are:

10 SEQ ID NO. 19: Sense primer: TGTGATCTGCCTCAGACCCAC

SEQ ID NO. 20: Antisense primer: TCATTCCTTCCTCCTTAATCTTTCTTG

The PCR products are inserted in the eukaryote expression vector pPicZ α -TOPO under the control of the hybrid promoter AOX1 inducible by methanol (TOPOTM-cloning; Invitrogen Corp.).

15 This vector permits the heterologous expression of eukaryote proteins in the yeast *Pichia pastoris*.

After checking of the nucleotide sequence of the region of the vector coding for the recombinant proteins, the vector is linearized by the PmeI restriction enzyme, and the *P. pastoris* yeast strain (Invitrogen) is transformed with these recombinant
20 expression vectors.

b) Heterologous expression in *P. pastoris* and purification of the natural wild-type IFN α -21 and mutated IFN α -21 proteins

Two saturated pre-cultures of 50 mL of BMGY medium (2% Peptone, 1% yeast
25 extract, 1.34% YNB, 1% Glycerol, 100 mM potassium phosphate, 0.4 mg/Liter biotin pH 6.0) containing a clone coding for natural wild-type IFN α -21 or that coding for A42G, Q102K, Q114H/V127D, or K179E mutated IFN α -21, were carried out for 24-48 hours at 30°C at an agitation of 200 rotations per minute (rpm).

When the culture reaches a saturating cellular density (corresponding to an
30 optical density of 12 measured at a wavelength of 600 nm), it is used to inoculate, at 5 OD/mL, 250 mL of BMMY medium (2% Peptone, 1% yeast extract, 1.34% YNB, 0.5%

Methanol, 100 mM potassium phosphate, 0.4 mg/Liter biotin pH 6.0).

The expression of the protein is then induced by methanol at a final concentration of 1%, for 24 hours at 30 °C, with an agitation of the culture flask at 180 rpm.

- 5 Due to the presence of the signal peptide sequence of the "alpha factor", upstream of the coding sequence, the proteins are secreted by the yeasts in the culture medium. The alpha factor is naturally cleaved during the processing.

The suspension is centrifuged and the protein is purified by HPLC starting from the obtained supernatant.

- 10 In a pre-started step, an ultrafiltration (Labscale, cut-off 5000Da, Millipore) followed by a dialysis permits a ten times concentration of the yeast supernatant in a buffer of 50 mM Tris-Cl pH 9.0, 25 mM NaCl.

- 15 The first chromatographic step permits protein recovery by affinity on a blue sepharose column (Amersham Pharmacia). The presence of the protein in the collected fractions is verified, on the one hand by electrophoresis of SDS PAGE type and on the other hand by immuno-detection by a specific antibody directed against the IFN α -21 protein. At this step, the purity of the protein of interest is higher than 75%.

- 20 In a second purification step, a gel filtration permits buffer exchange of the collected fractions corresponding to IFN α -21 proteins against 50 mM Tris pH 9.0, 25 mM NaCl.

The last step of the purification consists of a separation of the proteins on an ion exchange chromatography column.

- 25 The fractions containing the recombinant protein are injected on an anion exchange column (ResourceQ 6.0 mL, Pharmacia) equilibrated beforehand in Tris 50 mM pH 9, NaCl 25 mM buffer. The elution of the proteins is carried out by the migration of a gradient between 0,025 and 1 M NaCl in the Tris 50 mM pH 9 buffer.

The purity of the protein of interest is estimated on SDS/PAGE gel and the protein concentrations were measured by densitometry (Quantity one, Biorad) and BCA assay (bicinchoninic acid and copper sulfate, Sigma).

- 30 Purified natural wild-type IFN α -21 and A42G, Q102K, Q114H/V127D, or K179E mutated IFN α -21 proteins obtained according to this protocols, eventually

scaled-up to produce higher amount of proteins, are used for the functional tests described below.

Example 4. Evaluation of immunomodulatory activity of natural wild-type IFN α -21 and A42G, Q114H/V127D, or K179E mutated IFN α -21

IFNs type I (IFN alpha and IFN beta) are able to modulate certain functions of the immune system. They have been demonstrated to increase the dendritic cells (DC) maturation: increase in the expression of MHC class I (HLA-ABC) and II (HLA-DR) molecules, increase in the expression of the molecules involved in the co-stimulation of the T-lymphocytes, CD80, CD86 and CD83 molecules and increase in the stimulating function of T-lymphocyte.

a) Effect of A42G, Q114H/V127D, or K179E mutated IFN α -21 on dendritic cell maturation.

Immunomodulatory activity of A42G, Q114H/V127D, or K179E mutated IFN α -21 was first investigated on dendritic cells maturation and compared to that of wild-type IFN α -2 chosen as representative of commercial Intron A product.

To do so, dendritic cells were first generated from adult peripheral blood monocytes cultivated in the presence of GM-CSF and IL-4 cytokines. After purification using a CD14+ cells purification kit, these dendritic cells were placed in presence of 100 ng/mL of wild-type IFN α -2 or A42G, Q114H/V127D, or K179E mutated IFN α -21 and their phenotype was determined by FACS analysis aiming at looking for the expression of the MHC class I and II molecules and the CD40, CD80, CD86, CD83 and CD1a markers. The maturation state of these dendritic cells has also been compared to that obtained without IFN α treatment, to provide a control with non-stimulated dendritic cells.

The median value of the measures of fluorescence intensity for each marker and for the three experimental conditions, expressed as arbitrary unit, are presented in the following table:

	HLA ABC	HLA DR	CD40	CD80	CD86	CD83	CD1a
No stimulation	64	133	24	25	14	15	26
Wild-type IFN α -2	87	281	331	76	45	15	155
A42G mutated IFN α -21	76	127	117	37	5	8	209
Q114H/V127D mutated IFN α -21	68	122	163	46	8	8	191
K179E mutated IFN α -21	181	322	491	87	44	14	127

The results of this test demonstrate that the K179E mutated IFN α -21 protein possesses a high capacity to stimulate dendritic cell maturation, this stimulatory effect being higher than that of the wild-type IFN α -2.

5

b) Effect of Q114H/V127D, or K179E mutated IFN α -21 on cytokine release by T lymphocytes

Immunomodulatory activity of Q114H/V127D, or K179E mutated IFN α -21 was also investigated by measuring cytokine release by T lymphocytes placed in presence of the corresponding mutated IFN α -21 proteins and with or without a strong antigen (SEB) in order to mimic an immune response against an aggression. This test was also performed in presence of wild-type IFN α -2 used as control and chosen as representative of the Intron A commercial product.

To do so, peripheral blood mononuclear cells (PBMC) were isolated from healthy donors and stimulated for 16 hours in an appropriate medium containing anti-CD3 and anti-CD28 antibodies or SEB. In each culture was added 4 μ g/mL of wild-type IFN α -2 or Q114H/V127D, or K179E mutated IFN α -21. After stimulation, T lymphocytes were extracellularly labelled with anti-CD3, anti-CD4 and anti-CD69 antibodies or anti-CD3, anti-CD8 and anti-CD69 antibodies, and intracellularly labelled with specific antibodies directed against Th1-type cytokines (IFN-gamma) or Th2-type cytokines (IL-10). Fluorescent cells were analysed using FACScalibur and CellQuest software.

The results obtained indicate that mutated IFN α -21 proteins and wild-type

IFN α -2 do not stimulate IL-10 and IFN-gamma release and, thus, do not activate T lymphocytes in absence of SEB. In contrast, mutated IFN α -21 proteins and wild-type IFN α -2 stimulate cytokines (IL-10 and IFN-gamma) release by SEB-activated T-lymphocytes as shown in the table below. This table represents the cytokine release by

5 T-lymphocytes in presence of SEB, expressed as percentage of the CD4+ CD69+ cells or CD8+ CD69+ cells for the CD4+ T-lymphocytes and CD8+ T-lymphocytes, respectively, and the percentage of CD69+ cells on total cells.

T-lymphocyte		IFN gamma	IL-10	CD69+ cells/total
CD4+ CD69+	Negative control	11.9	7.5	1.26
	Wild-type IFN α -2	19.6	24.68	2.7
	Q114H/V127D IFN α -21	38.9	14.6	4.67
	K179E IFN α -21	29.5	15.1	3.84
CD8+ CD69+	Negative control	8.73	0.65	4.69
	Wild-type IFN α -2	16.37	4.26	10.02
	Q114H/V127D IFN α -21	32.24	4.91	14.98
	K179E IFN α -21	28.28	3.8	13.48

10 These results clearly demonstrate that Q114H/V127D mutated IFN α -21 and K179E mutated IFN α -21 strongly stimulate cytokine release (IFN gamma and IL-10) by CD4+ and CD8+ T-lymphocytes previously activated by SEB antigen. In this test, the interferon gamma production by T-lymphocytes is higher in presence of Q114H/V127D mutated IFN α -21 or K179E mutated IFN α -21 than in presence of wild-

15 type IFN α -2.

c) Effect of Q114H/V127D or K179E mutated IFN α -21 on cytokine release by monocytes

Finally, immunomodulatory activity of Q114H/V127D or K179E mutated

20 IFN α -21 was investigated by measuring cytokine release by monocytes in absence or in presence of a bacterial toxic agent (LPS). This test was also performed in presence of

wild-type IFN α -2 used as control and chosen as representative of the Intron A commercial product.

To do so, human peripheral blood mononuclear cells (PBMC) were isolated from healthy donors and their phenotype was analyzed to determine the relative amount of CD64+ CD4dim cells (CD64 and CD4dim are markers for blood monocytes). After an over-night culture, these PBMC were incubated in the culture medium alone (not stimulated cells) or in presence of LPS (stimulated cells). In each culture, 4 μ g/mL of wild-type IFN α -2 or mutated IFN α -21 was added. After culture, cells were extracellularly labelled with anti-CD64 and anti-CD4dim, and intracellularly labelled with specific antibodies directed against Th1-type cytokines (TNF-alpha), IL-12 and IL-10.

Fluorescent cells were analyzed using FACScalibur and CellQuest software.

The results obtained indicate that mutated IFN α -21 proteins and wild-type IFN α -2 do not stimulate cytokines (IL-10, IL-12 and TNF-alpha) release in absence of LPS. In contrast, in presence of LPS, Q114H/V127D and K179E mutated IFN α -21 proteins and wild-type IFN α -2 stimulate cytokines (IL-10, IL-12 and TNF-alpha) release by monocytes as shown in the table below. This table represents cytokine release by monocytes in presence of LPS, expressed as percentage of the CD64+ CD4dim cells, and the percentage of CD4dim CD64+ cells on total cells.

	IL-10	IL-12	TNF- α	CD4dim CD64+ cells/total
No stimulation	16.21	8.52	13.88	3.1
Wild-type IFN α -2	49.34	34.48	50.87	2.71
Q114H/V127D IFN α -21	50.63	31.81	56.5	2.31
K179E IFN α -21	60.14	36.42	60.16	4.43

Example 5. Evaluation of *in vitro* antiproliferative activity of A42G, Q102K, Q114H/V127D, and K179E mutated IFN α -21

a) on the human lymphoblasts of Daudi Burkitt's cell line proliferation

These tests are carried out on A42G, Q102K, Q114H/V127D, and K179E

mutated IFN α -21 proteins and wild-type IFN α -21 protein. Cells (human Daudi Burkitt's lymphoma cell line, hereinafter called "Daudi cells") cultivated beforehand in a RPMI 1640 medium (supplemented with 10% fetal calf serum and 2 mM of L-Glutamine) are inoculated in 96-well plates at the cellular density of $4 \cdot 10^4$ cells/ well.

- 5 In each well, Daudi cells are placed in contact of increasing concentrations of either mutated or wild-type IFN α -21 proteins. For each IFN α -21 to be characterized, final concentrations of 0.003 pM to 600 nM are tested.

The Daudi cells are then incubated for 66 h at 37 °C under 5% CO₂ after which the Uptibblue reagent (Uptima) is added to the cultures. The rate of cell proliferation is
10 quantified by measuring the fluorescence emitted at 590nm (excitation 560nm) after an additional period of incubation of 4 hours.

The antiproliferative activity of mutated or wild-type IFN α -21 is based on the measurements of the IC₅₀ corresponding to the concentration of IFN α -21 inhibiting 50% of the cell growth.

- 15 For each experimental condition, at least three experiments have been carried out in triplicates, which permits the determination of the average IC₅₀ value for each IFN α -21. The ratio corresponding to the value of the IC₅₀ of the mutated protein over the value of the wild-type protein permits the comparison. The results are collected in the following table (in brakets is noted the standard deviation):

	Wild-type IFNα-21	A42G IFNα-21	Q102K IFNα-21	Q114H/V127D IFNα-21	K179E IFNα-21
IC ₅₀ (pM)	1.02	2.55	1.05	13.92	3.73
Ratio wild-type/ mutated	-	2.15 (0.78)	1.30 (0.24)	13.10 (3.06)	3.72 (0.83)

20

This test demonstrates that the cellular antiproliferative activity on Daudi cells of the A42G, Q114H/V127D, and K179E mutated IFN α -21 proteins is lower than that of wild-type IFN α -21. In particular, the cellular antiproliferative activity on Daudi cells is approximately 10 to 16-fold lower in presence of Q114H/V127D IFN α -21 by
25 comparison with wild-type IFN α -21.

b) on the TF-1 erythroleukemia cell line

The effect of A42G, Q114H/V127D, and K179E mutated IFN α -21 was also evaluated on TF-1 erythroleukemia cell line. This test was also performed in presence of wild-type IFN α -2 used as control and chosen as representative of the Intron A commercial product.

- 5 To do so, TF-1 cells were placed in contact of increasing concentrations of mutated IFN α -21 or wild-type IFN α -2 (0.001 to 1000 ng/mL) and the cell proliferation measured.

The results are expressed as the IC30 corresponding to the IFN α concentration inhibiting proliferation of 30% of cells and collected in the following table:

	Wild-type IFN α -2	A42G IFN α -21	Q114H/V127D IFN α -21	K179E IFN α -21
10 IC30 (ng/mL)	0.66	2.33	1.97	1.62

These data indicate that the three mutated IFN α -21 have a weak antiproliferative effect on TF-1 cells, and this effect is similar to that of wild-type IFN α -2, suggesting that the A42G, Q114H/V127D, and K179E mutated IFN α -21's hematologic toxicity is not superior than that of wild-type IFN α -2.

15

Example 6. Evaluation of the antiviral activity of A42G, Q114H/V127D, and K179E mutated IFN α -21

The IFNs play an important role in the antiviral defence. The IFN antiviral activity is partly due to IFNs induced enzymatic systems, such as:

- 20 - The 2'5' oligoadenylate synthetase, an enzyme which catalyzes the adenosine oligomere synthesis. These oligomeres activate the RNase L, an endoribonuclease which destroy the viral RNA once activated.
- The Mx proteins (GTPases) which inhibit the synthesis and/or the maturation of viral transcripts. This activity is mainly exerted on the influenza virus.
- 25 - The PKR protein (or p68 kinase) which is activated by the double-stranded RNA. The activated PKR inhibits protein synthesis.

The IFNs antiviral activity is also induced by other mechanisms such as, in the case of retroviruses, the inhibition of viral particles entry into the cells, the replication, the binding, the exit of the particles and the infective power of viral particles.

Finally, the IFNs exert an indirect antiviral activity by modulating certain functions of the immune system, in particular by favoring the response to cellular mediation (including an increase of the MHC class I and II molecules, increase of IL-12 and IFN-gamma production, increase of the CTL activities, among others).

5 The antiviral activity of A42G, Q114H/V127D, and K179E mutated IFN α -21 has been evaluated both *in vitro* in cell culture and *in vivo* in mouse model. Both tests have been carried out in parallel with wild-type IFN α -2 used as control and chosen as representative of the Intron A commercial product.

10 a) Antiviral activity *in vitro* in cell culture

This assay permits evaluation of the antiviral activity of A42G, Q114H/V127D, and K179E mutated IFN α -21 and wild-type IFN α -2 in cell culture using the vesicular stomatitis virus (VSV).

To do so, WISH human epithelial cells are cultivated for 24 hours in the
15 presence of decreasing concentrations of mutated IFN α -21 and wild-type IFN α -2. Then, the cells are infected by the virus of vesicular stomatitis (VSV) during 24 to 48 additional hours and the cell lysis is measured.

The antiviral effect of the different IFN α tested is determined by comparing the IC50 value corresponding to the IFN concentration inhibiting 50% of cell lysis induced
20 by the VSV.

A similar experiment has been carried out two times, and the average IC50 values measured are presented in the following table:

	Wild-type IFN α -2	A42G IFN α -21	Q114H/V127D IFN α -21	K179E IFN α -21
IC50 (ng/mL)	4	14	22	25

Thus, in cell culture infected with VSV, the A42G, Q114H/V127D, and K179E
25 mutated IFN α -21 have a lower antiviral activity than the wild-type IFN α -2.

b) Antiviral activity *in vivo* in mouse model

This test *in vivo* is performed in EMCV (Encephalomyocarditis virus) mouse model.

Human IFNs exhibit dose-dependent antiviral activity in the mouse which is in general 100 to 1,000 fold less than that exhibited by the same amount of mouse IFN (Meister et al. (1986). J. Gen. Virol. 67, 1633-1644).

Intraperitoneal injection of mice with Encephalomyocarditis virus (EMCV) gives rise to a rapidly progressive fatal disease characterized by central nervous system involvement and encephalitis (Finter NB (1973). Front Biol. 2: 295-360). Mouse and human interferon-alpha have both been shown to be effective in protecting mice against lethal EMCV infection (Tovey and Maury (1999). J. IFN Cytokine Res. 19: 145-155).

Groups of 20, six-week old Swiss mice were infected intraperitoneally (ip) with 100 x LD₅₀ EMCV and treated one hour later, and then once daily for 3 days thereafter with 2 µg of A42G, Q114H/V127D, K179E mutated IFNα-21 or wild-type IFNα-2 preparations. A control group was performed with animals having been treated with excipient only. The animals were followed daily for survival for 21 days.

Results are presented in Figure 6 and indicate that the relative survival rate of the mice which have been treated with A42G, Q114H/V127D, or K179E mutated IFNα-21 is much higher than the survival rate of the non-treated mice but remains similar to that observed for the mice which have been treated with wild-type IFNα-2.

All of these results demonstrate that A42G, Q114H/V127D, and K179E mutated IFNα-21 possess unique biological properties.

CLAIMS

1. An isolated polynucleotide comprising all or part of:
 - a) the nucleotide sequence SEQ ID NO. 1 provided that such nucleotide sequence comprises at least one SNP selected from the group consisting of c794g, c973a,
5 g1011c, t1049a, t1155a, a1204g, and t1265c; or
 - b) a nucleotide sequence complementary to a nucleotide sequence under a).
2. The isolated polynucleotide of claim 1, comprising nucleotides 670 to 1239 of SEQ ID NO. 1, provided that the sequence contains at least one coding SNP selected from the group consisting of c794g, c973a, g1011c, t1049a, t1155a, and a1204g.
- 10 3. The isolated polynucleotide of claim 1, wherein said polynucleotide is composed of at least 10 nucleotides.
4. An isolated polynucleotide that codes for a polypeptide comprising all or part of the amino acid sequence SEQ ID NO. 2, and having at least one coding SNP selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and
15 K179E.
5. An isolated polynucleotide that codes for a polypeptide comprising all or part of the amino acid sequence SEQ ID NO. 2, and having the two coding SNPs Q114H and V127D.
6. An isolated polynucleotide that codes for a polypeptide comprising all or part of the
20 amino acid sequence SEQ ID NO. 2, and having the coding SNP K179E.
7. A method for identifying or amplifying all or part of a polynucleotide having 80 to 100% identity with nucleotide sequence SEQ ID NO. 1 comprising hybridizing, under appropriate hybridization conditions, said polynucleotide with the polynucleotide of claim 1.
- 25 8. A method for genotyping all or part of a polynucleotide having 80 to 100% identity with nucleotide sequence SEQ ID NO. 1 comprising the steps of amplifying a region of interest in the genomic DNA of a subject or a population of subjects, and determining the allele of at least one positions in the nucleotide sequence SEQ ID

- NO. 1 chosen from the group consisting of 794, 973, 1011, 1049, 1155, 1204, and 1265.
9. The method of claim 8, wherein the genotyping is carried out by minisequencing.
10. A recombinant vector comprising a polynucleotide according to claim 1.
- 5 11. A host cell comprising a recombinant vector according to claim 10.
12. A method for separating a polypeptide, comprising cultivating a host cell according to claim 11 in a culture medium and separating said polypeptide from the culture medium.
13. The polypeptide encoded by the isolated polynucleotide of claim 1.
- 10 14. An isolated polypeptide comprising all or part of amino acid sequence SEQ ID NO. 2 and having at least one coding SNP selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E.
- 15 15. The polypeptide according to claim 13, comprising amino acids 24 through 189 of the amino acid sequence SEQ ID NO. 2, and having at least one coding SNP selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E.
16. The polypeptide according to claim 13, comprising amino acids 24 through 189 of the amino acid sequence SEQ ID NO. 2, and having the two coding SNPs Q114H and V127D.
- 20 17. The polypeptide according to claim 13, comprising amino acids 24 through 189 of the amino acid sequence SEQ ID NO. 2, and having the coding SNP K179E.
18. A method for obtaining an immunospecific antibody, comprising immunizing an animal with the polypeptide according to claim 13, and collecting said antibody from said animal.
- 25 19. The immunospecific antibody resulting from the method of claim 18.
20. A method for identifying an agent among one or more compounds to be tested which activates or inhibits the activity of an isolated polypeptide comprising all or part of amino acid sequence SEQ ID NO. 2 and having at least one coding SNP

selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E, said method comprising:

- a) providing host cells comprising the recombinant vector according to claim 10;
 - b) contacting said host cells with said compounds to be tested,
 - 5 c) determining the activating or inhibiting effect upon the activity of said polypeptide whereby said activating or inhibiting agent is identified.
21. A method for identifying an agent among one or more compounds to be tested whose activity is potentiated or inhibited by an isolated polypeptide comprising all or part of amino acid sequence SEQ ID NO. 2 and having at least one coding SNP
- 10 selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E, said method comprising:
- a) providing host cells comprising the recombinant vector according to claim 10;
 - b) contacting said host cells with said compounds to be tested,
 - c) determining the potentiating or inhibiting effect upon the activity of said agent
 - 15 whereby said potentiated or inhibited agent is identified.
22. A method for analyzing the biological characteristics of a subject, comprising performing at least one of the following steps:
- a) Determining the presence or the absence of the polynucleotide according to claim 1 in the genome of a subject;
 - 20 b) Determining the level of expression of the polynucleotide according to claim 1 in a subject;
 - c) Determining the presence or the absence of the polypeptide according to claim 13 in a subject;
 - d) Determining the concentration of the polypeptide according to claim 13 in a
 - 25 subject; or
 - e) Determining the functionality of the polypeptide according to claim 13 in a subject.
23. A therapeutic agent comprising one or more compounds selected from the group

- consisting of an isolated polynucleotide comprising all or part of the nucleotide sequence SEQ ID NO. 1 provided that such nucleotide sequence comprises at least one SNP selected from the group consisting of c794g, c973a, g1011c, t1049a, t1155a, a1204g, and t1265c, or a nucleotide sequence complementary to said nucleotide sequence; a recombinant vector comprising said polynucleotide; a host cell comprising said recombinant vector; an isolated polypeptide comprising all or part of amino acid sequence SEQ ID NO. 2 and having at least one coding SNP selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E; an antibody specific for said polypeptide.
24. A method for preventing or treating in an individual a disease selected from the group consisting of cancers and tumors, infectious diseases, immunologically and auto-immunologically related diseases, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments, comprising administering to said individual a therapeutically effective amount of the agent of claim 23, plus a pharmaceutically acceptable excipient.
25. The method of claim 24, wherein said cancers and tumors comprise metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas, and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising Kaposi's sarcoma in the case of AIDS.
26. The method of claim 24, wherein said metabolic diseases comprise non-immune associated diseases such as obesity.
27. The method of claim 24, wherein said infectious diseases comprise viral infections including chronic hepatitis B and C and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.
28. The method of claim 24, wherein said diseases of the central nervous system comprise Alzheimer's disease, Parkinson's disease, schizophrenia and depression.
29. The method of claim 24, wherein said immunologically and auto-immunologically related diseases comprise the rejection of tissue or organ grafts, allergies, asthma,

psoriasis, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis.

30. A method for preventing or treating in an individual a disease selected from the group consisting of healing of wounds, anemia in dialyzed patient, and/or osteoporosis, comprising administering to said individual a therapeutically effective amount of the agent of claim 23, plus a pharmaceutically acceptable excipient.
31. A method for increasing or decreasing the activity in a subject of the polypeptide according to claim 13 comprising administering a therapeutically effective quantity of one or more of: an isolated polynucleotide comprising all or part of the nucleotide sequence SEQ ID NO. 1 provided that such nucleotide sequence comprises at least one SNP selected from the group consisting of c794g, c973a, g1011c, t1049a, t1155a, a1204g, and t1265c, or a nucleotide sequence complementary to said nucleotide sequence; a recombinant vector comprising said polynucleotide; a host cell comprising said recombinant vector, wherein said host cell may be obtained from said subject to be treated; an isolated polypeptide comprising all or part of amino acid sequence SEQ ID NO. 2 and having at least one coding SNP selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E; an antibody specific for said polypeptide; and a pharmaceutically acceptable excipient.
32. A method for preventing or treating in an individual a disorder or a disease linked to the presence in the genome of said individual of the polynucleotide of claim 1, comprising administering a therapeutically effective amount of one or more of: an isolated polynucleotide comprising all or part of the nucleotide sequence SEQ ID NO. 1 and having at least one SNP selected from the group consisting of c794g, c973a, g1011c, t1049a, t1155a, a1204g, and t1265c, or a nucleotide sequence complementary to said nucleotide sequences; a recombinant vector comprising one of said polynucleotides; a host cell comprising said recombinant vector; an isolated polypeptide comprising all or part of amino acid sequence SEQ ID NO. 2 and having at least one coding SNP selected from the group consisting of A42G, Q102K, Q114H, V127D, C162stop, and K179E; an antibody specific for one of said

polypeptides; and a pharmaceutically acceptable excipient.

33. A method for determining statistically relevant associations between at least one SNP selected from the group consisting of c794g, c973a, g1011c, t1049a, t1155a, a1204g, and t1265c, in the IFN α -21 gene, and a disease or resistance to disease comprising:

- a) Genotyping a group of individuals;
- b) Determining the distribution of said disease or resistance to disease within said group of individuals;
- c) Comparing the genotype data with the distribution of said disease or resistance to disease; and
- d) Analyzing said comparison for statistically relevant associations.

34. A method for diagnosing or determining a prognosis of a disease or a resistance to a disease comprising detecting at least one SNP selected from the group consisting of c794g, c973a, g1011c, t1049a, t1155a, a1204g, and t1265c, in the IFN α -21 gene.

35. A method for identifying a compound among one or more compounds to be tested having a biological activity substantially similar to the activity of Q114H/V127D mutated IFN α -21 gene product, said method comprising the steps of:

- a) Determining the biological activity of said compound, such as dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative activity on Daudi Burkitt's cell line, cellular antiproliferative activity on TF-1 cell line;
- b) Comparing the activity determined in step a) of said compound with the activity of the Q114H/V127D mutated IFN α -21 gene product.
- c) Determining, on the basis of the comparison carried out in step b), whether said compound has a substantially similar activity compared to that of the Q114H/V127D mutated IFN α -21 gene product.

36. The method according to claim 35, wherein said compounds to be tested are

identified from synthetic peptide combinatorial libraries, high-throughput screening, or designed by computer-aided drug design to have the same three-dimensional structure as that of the polypeptide of SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2, provided that said amino acid sequences comprise the Q114H and V127D SNPs.

37. The compound identified by the method of claim 35.

38. A method for identifying a compound among one or more compounds to be tested having a biological activity substantially similar to the activity of K179E mutated IFN α -21 gene product, said method comprising the steps of:

- a) Determining the biological activity of said compound, such as dendritic cell maturation, cytokine release by CD4+ or CD8+ T-lymphocytes, cytokine release by monocytes, in vitro or in vivo antiviral activity, cellular antiproliferative activity on Daudi Burkitt's cell line, cellular antiproliferative activity on TF-1 cell line;
- b) Comparing the activity determined in step a) of said compound with the activity of the K179E mutated IFN α -21 gene product.
- c) Determining, on the basis of the comparison carried out in step b), whether said compound has a substantially similar activity compared to that of the K179E mutated IFN α -21 gene product.

39. The method according to claim 38, wherein said compounds to be tested are identified from synthetic peptide combinatorial libraries, high-throughput screening, or designed by computer-aided drug design to have the same three-dimensional structure as that of the polypeptide of SEQ ID NO. 2, or of amino acid sequence comprising the amino acids included between positions 24 and 189 of the amino acid sequence SEQ ID NO. 2, provided that said amino acid sequences comprise the K179E SNP.


40. The compound identified by the method of claim 38.

41. A method for preventing or treating in an individual a disease selected from the group

consisting of cancers and tumors, infectious diseases, immunologically and auto-immunologically related diseases, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments, comprising administering to said individual a therapeutically effective amount of the agent of claim 37 or 40, plus a pharmaceutically acceptable excipient.


42. The method of claim 41, wherein said cancers and tumors comprise metastasizing renal carcinomas, melanomas, lymphomas comprising follicular lymphomas, and cutaneous T cell lymphoma, leukemias comprising hairy-cell leukemia, chronic lymphocytic leukemia and chronic myeloid leukemia, cancers of the liver, neck, head and kidneys, multiple myelomas, carcinoid tumors and tumors that appear following an immune deficiency comprising Kaposi's sarcoma in the case of AIDS.
43. The method of claim 41, wherein said infectious diseases comprise viral infections including chronic hepatitis B and C and HIV/AIDS, infectious pneumonias, and venereal diseases, such as genital warts.
44. The method of claim 41, wherein said immunologically and auto-immunologically related diseases comprise the rejection of tissue or organ grafts, allergies, asthma, psoriasis, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis.
45. The method of claim 41, wherein said diseases of the central nervous system comprise Alzheimer's disease, Parkinson's disease, schizophrenia and depression.
46. The method of claim 41, wherein said metabolic diseases comprise non-immune associated diseases such as obesity.

FIGURE 1



2/6

FIGURE 2



3/6




FIGURE 3

4/6

FIGURE 4






FIGURE 5



6/6

FIGURE 6



SEQUENCE LISTING

<110> Escary, Jean-Louis

<120> New Polynucleotides and Polypeptides of the IFNalpha-21 Gene

<130> 021349/0012

<150> FR 0104404

<151> 2001-03-30

<160> 20

<170> PatentIn version 3.1

<210> 1

<211> 2001

<212> DNA

<213> Homo sapiens

<400> 1

```
atTTTgtcat ataaagcaaa attcaaagct tcatatatat actatgagaa aaatttttaa 60
aaattattga ttcatatTTT tagcagtttt gaatgattaa ctatgtaatt atattcatat 120
tattaatgtg tatttatata gatttttatt ttgcatatgt aatttcataa aacaaaattt 180
acatgaacaa attacattaa aagttattcc acaaataaac ttatcaaatt aagttaaatg 240
tcaatagctt ttaaacttag atttttagttt aacatttctg tcattcttta ctttgaataa 300
aaagagcaaa ctttatagtt tttatctgtg aagtagagat atacatatta tacataaata 360
gataagccaa atctgtgtta ctaaaatttc atgaagattt caattagaaa aaaataccat 420
aaaatgtttt gagtgcaggg gaaaaatagg caatgatgaa aaaaaatgaa aaacatctgt 480
aaacacatgt agagagtgca taaagaaagc aaaaacagag atagaaagta aaactagggc 540
atttagaaaa tggaaattag tatgttcact atttaagacc tacgcacaga gcaaagtctt 600
cagaaaacct agaggccaag gttcaagggt acccatctca agtagcctag caatattggc 660
aacatcccaa tggccctgtc cttttcttta ctgatggccg tgctggtgct cagctacaaa 720
tccatctgtt ctctgggctg tgatctgcct cagaccaca gcctgggtaa taggaggggc 780
ttgatactcc tggcacaaat gggaagaatc tctcctttct cctgcctgaa ggacagacat 840
gactttggat tccccagga ggagtttgat ggcaaccagt tccagaaggc tcaagccatc 900
tctgtcctcc atgagatgat ccagcagacc ttcaatctct tcagcacaaa ggactcatct 960
```

```

gctacttggg aacagagcct cctagaaaaa ttttccactg aacttaacca gcagctgaat 1020
gacctggaag cctgcgtgat acaggagggtt ggggtggaag agactcccct gatgaatgtg 1080
gactccatcc tggctgtgaa gaaatacttc caaagaatca ctctttatct gacagagaag 1140
aaatacagcc cttgtgcctg ggaggttgtc agagcagaaa tcatgagatc cttctcttta 1200
tcaaaaattt ttcaagaaag attaaggagg aaggaatgaa acctgtttca acatggaaat 1260
gatctgtatt gactaataca ccagtcaca cttctatgac ttctgccatt tcaaagactc 1320
atctctccta taaccaccgc atgagttgaa tcaaaaatct cagatctttt caggagtgtg 1380
aggaaacatc atgtttacct gtgcaggcac tagtccttta cagatgacca tgctgataga 1440
tctaattatc tatctattga aatatttatt tatttattag atttaaatta tttttgtcca 1500
tgtaatatta tgtgtacttt tacatttgtt tataatcaaaa tatgtgattt atatttagtc 1560
aatatattat ttcttttaat taaattttac tattaaaact tcttatatta tttgtttatt 1620
ctttaataaa gaaataccaa gcccaaattg gcaatctcat taaagaatgg atggtacaat 1680
tcattttacc atcatcattg tatccaaatt gtaagtaaaa attgactttc tctaagcgag 1740
gttttatatt gcccttagga tatccaggtg aacataacaa ataccgtttt cgctttcttg 1800
tatcttttat ttttgtaagg aaaataataa ctatactttc taataacctg tacattaaat 1860
gctatagtga gaagaaataa aaacaaatga aattcagtaa aactgaagca aggcatatca 1920
aaatTTTTTT taaaaaagta gtagatatcc tctatagcag acaagtagac atctaagtgc 1980
aagtgtccat tggtaacctg a 2001

```

```

<210> 2
<211> 189
<212> PRT
<213> Homo sapiens

```

```

<400> 2

```

```

Met Ala Leu Ser Phe Ser Leu Leu Met Ala Val Leu Val Leu Ser Tyr
1           5           10          15

```

```

Lys Ser Ile Cys Ser Leu Gly Cys Asp Leu Pro Gln Thr His Ser Leu
20           25           30

```

```

Gly Asn Arg Arg Ala Leu Ile Leu Leu Ala Gln Met Gly Arg Ile Ser
35           40           45

```

```

Pro Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu
50           55           60

```

Glu Phe Asp Gly Asn Gln Phe Gln Lys Ala Gln Ala Ile Ser Val Leu
 65 70 75 80
 His Glu Met Ile Gln Gln Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser
 85 90 95
 Ser Ala Thr Trp Glu Gln Ser Leu Leu Glu Lys Phe Ser Thr Glu Leu
 100 105 110
 Asn Gln Gln Leu Asn Asp Met Glu Ala Cys Val Ile Gln Glu Val Gly
 115 120 125
 Val Glu Glu Thr Pro Leu Met Asn Val Asp Ser Ile Leu Ala Val Lys
 130 135 140
 Lys Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser
 145 150 155 160
 Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile Met Arg Ser Phe Ser
 165 170 175
 Leu Ser Lys Ile Phe Gln Glu Arg Leu Arg Arg Lys Glu
 180 185

<210> 3
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 3
 ggttcaaggt tacccatctc

20

<210> 4
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 4
 ggttcaaggt tacccatctc

20

<210> 5
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 5
 ggttcaaggt tacccatctc

20

<210> 6
 <211> 20

<212> DNA
<213> Homo sapiens

<400> 6
tttgaaatgg cagaagtcac 20

<210> 7
<211> 20
<212> DNA
<213> Homo sapiens

<400> 7
gagggccttg atactcctgg 20

<210> 8
<211> 20
<212> DNA
<213> Homo sapiens

<400> 8
gagagattct tcccatttgt 20

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
actcatctgc tacttgggaa 20

<210> 10
<211> 20
<212> DNA
<213> Homo sapiens

<400> 10
aaatTTTTtct aggaggctct 20

<210> 11
<211> 20
<212> DNA
<213> Homo sapiens

<400> 11
ttttccactg aacttaacca 20

<210> 12
<211> 20
<212> DNA

<213> Homo sapiens

<400> 12

gcttccaggt cattcagctg

20

<210> 13

<211> 20

<212> DNA

<213> Homo sapiens

<400> 13

agcctgcgtg atacaggagg

20

<210> 14

<211> 20

<212> DNA

<213> Homo sapiens

<400> 14

ggggagtctc ttccacccca

20

<210> 15

<211> 20

<212> DNA

<213> Homo sapiens

<400> 15

gagaagaaat acagcccttg

20

<210> 16

<211> 20

<212> DNA

<213> Homo sapiens

<400> 16

gctctgacaa cctcccaggc

20

<210> 17

<211> 20

<212> DNA

<213> Homo sapiens

<400> 17

tgagatcctt ctctttatca

20

<210> 18

<211> 20

<212> DNA

<213> Homo sapiens

<400> 18

taatctttct tgaaaaattt

20

<210> 19

<211> 21

<212> DNA

<213> Homo sapiens

<400> 19

tgtgatctgc ctcagaccca c

21

<210> 20

<211> 27

<212> DNA

<213> Homo sapiens

<400> 20

tcattccttc ctccttaate tttcttg

27

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number
WO 02/079249 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
G01N 33/68, C12N 15/85, 15/63, C07K 14/56, 16/00,
16/24, A61K 38/21, A61P 9/00, 31/12, 35/00, 37/00

(21) International Application Number: PCT/EP02/04082

(22) International Filing Date: 29 March 2002 (29.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01/04404 30 March 2001 (30.03.2001) FR

(71) Applicant (*for all designated States except US*): **GEN-ODYSSEE** [FR/FR]; Parc d'Affaires Technopolis, 3, avenue du Canada, Bat. Alpha, BP 810 Les Ulis, F-91974 Courtaboeuf (FR).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **ESCARY, Jean-Louis** [FR/FR]; 4, rue Moxouris, F-78510 Le Chesnay (FR).

(74) Agent: **SANTARELLI**; 14, avenue de la Grande-Armée, B.P. 237, F-75822 Paris (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
20 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN γ (A)-21 GENE

(57) Abstract: The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFN α -21 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFN α -21 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

WO 02/079249 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/04082

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12Q1/68	G01N33/68	C12N15/85	C12N15/63	C07K14/56
	C07K16/00	C07K16/24	A61K38/21	A61P9/00	A61P31/12
	A61P35/00	A61P37/00			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q C12N C07K G01N A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, SEQUENCE SEARCH, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ULLRICH A ET AL: "NUCLEOTIDE SEQUENCE OF A PORTION OF HUMAN CHROMOSOME 9 CONTAINING A LEUKOCYTE INTERFERON GENE CLUSTER" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 156, no. 3, 15 April 1982 (1982-04-15), pages 467-486, XP000605299 ISSN: 0022-2836 * see especially nucleotide 2386 within Fig.2 * abstract page 468, paragraph 2 page 483, line 6 - line 14; figures 2,10,11 --- -/--	1-4, 7-11, 13-15,22



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

27 May 2003

Date of mailing of the international search report

13/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

INTERNATIONAL SEARCH REPORT

Internation ication No

PCT/EP 02/04082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 84 00776 A (CETUS CORP) 1 March 1984 (1984-03-01)</p> <p>* see especially the nucleotide no.163 of the encoding sequence; as well as the claims *</p> <p>the whole document</p> <p>---</p>	1-4, 7, 8, 10-15, 22-24, 27
X	<p>US 4 801 685 A (PESTKA SIDNEY ET AL) 31 January 1989 (1989-01-31)</p>	1-4, 7-11, 13-15, 22
Y	<p>* see especially Figure 3-1, nucleotide 125, as well as Figure 9 *</p> <p>abstract; claims 1-5; figures 3, 4, 9</p> <p>---</p>	5, 6, 23-25, 29-34
X	<p>VELAN B ET AL: "Bovine interferon alpha genes. Structure and expression" EMBL, 1987, XP002187983</p> <p>* Accession number P05007; see especially amino acid residue no.102 *</p> <p>abstract</p> <p>---</p>	4, 14, 15
Y	<p>WO 01 25438 A (MAXYGEN INC ;CHEN TEDDY (US); HEINRICHS VOLKER (US); PATTEN PHILLI) 12 April 2001 (2001-04-12)</p> <p>* see especially SEQ ID NOS: 19, 22, 24 (nucleotide 393) *</p> <p>abstract; claims</p> <p>1, 20-26, 31, 41, 42, 60, 64, 66-80, 104-123</p> <p>page 1, line 25 - line 32</p> <p>page 9, line 3 - line 31</p> <p>page 85, line 1 -page 100, line 31</p> <p>---</p>	1-20, 22-34
Y	<p>HUSSAIN M ET AL.: "Identification of interferon-alpha7, -alpha14 and -alpha21 variants in the genome of a large human population"</p> <p>JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 16, 1996, pages 853-859, XP008015634</p> <p>abstract</p> <p>* see especially Fig.1 *</p> <p>page 853, column 2, paragraph 1; figures 1, 3; table 2</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-19, 22

INTERNATIONAL SEARCH REPORT

Internationl llication No

PCT/EP 02/04082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WEBER H ET AL.: "Single amino acid changes that render human IFN-alpha2 biologically active on mouse cells"</p> <p>THE EMBO JOURNAL, vol. 6, no. 3, 1987, pages 591-598, XP002242107 cited in the application * see especially Fig.'s 1 and 3, as well as table 2 * the whole document</p> <p>---</p>	20
Y	<p>SYVANEN A-CH ET AL: "IDENTIFICATION OF INDIVIDUALS BY ANALYSIS OF BIALLELIC DNA MARKERS, USING PCR AND SOLID-PHASE MINISEQUENCING"</p> <p>AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 52, no. 1, 1993, pages 46-59, XP002050638 ISSN: 0002-9297 the whole document</p> <p>---</p>	8,9,33, 34
Y	<p>WO 00 39280 A (VIRAGEN INC) 6 July 2000 (2000-07-06) abstract; claim 20</p> <p>---</p>	24-29,33
Y	<p>JANSEN R L H ET AL.: "Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer"</p> <p>JOURNAL OF IMMUNOTHERAPY, vol. 12, 1992, pages 70-73, XP001148923 the whole document</p> <p>---</p>	24,25, 31-34
Y	<p>MITA E ET AL.: "Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer"</p> <p>DIGESTIVE DISEASES AND SCIENCES, vol. 39, no. 5, 1995, pages 977-982, XP008016510 the whole document</p> <p>---</p>	24,27, 31-34
Y	<p>YAMADA R ET AL: "IDENTIFICATION OF 142 SINGLE NUCLEOTIDE POLYMORPHISMS IN 41 CANDIDATE GENES FOR RHEUMATOID ARTHRITIS IN THE JAPANESE POPULATION"</p> <p>HUMAN GENETICS, BERLIN, DE, vol. 106, 2000, pages 293-297, XP002947356 the whole document</p> <p>---</p>	24,29
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

Internation
PCT/EP 02/04082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	COHEN S ET AL: "CLONING, EXPRESSION AND BIOLOGICAL ACTIVITY OF A NEW VARIANT OF HUMAN INTERFERON ALPHA IDENTIFIED IN VIRUS INDUCED LYMPHOBLASTOID CELLS" DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, BASEL, CH, vol. 60, 1985, pages 111-122, XP002062570 the whole document ---	
P,A	FINK T ET AL.: "Biological characterization of three novel variants of IFN-alpha13 produced by human placental trophoblast" PLACENTA, vol. 22, September 2001 (2001-09), pages 673-680, XP001058217 the whole document -----	

INTERNATIONAL SEARCH REPORT

Intern: application No.
PCT/EP 02/04082**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 23-32 are directed to a therapeutic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the gene's expression products as related to the underlying polymorphisms.
2. ☒ Claims Nos.: 35-46
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 35-46

Present claims 35-46 relate to methods as well as compounds resulting from such methods, defined by reference to a desirable characteristic or property, namely in possessing a biological activity being substantially similar to the activity of the Q114H/V127D- or K179E-mutated IFNalpha-21 gene product

(claims 35 and 38), and further, in using compounds having the same three-dimensional structure as (parts of) the mutated polypeptide of SEQ ID NO:2 (claims 36, 37, 39 and 40), such methods and compounds being used for preventing or treating diseases (claims 41-46). Without comprising clear essential technical features allowing the person skilled in the art to understand what exactly is meant with '...substantially similar to the activity of the Q114H/V127D- or K179E-mutated IFNalpha-21 gene product...' or '...having the same three-dimensional structure...', it is without saying that such terms could be interpreted in any possible way. Thus, they are not fulfilling the requirements of giving a clear teaching about the content and the scope of these claims, and especially, how to execute the teaching of these claims successfully. In fact, these claims cover all possible methods and deriving compounds having these characteristics or properties without giving any clue in form of technical features how to do so, in contrast to the requirements of Article 6 PCT (need for support) and/or Article 5 PCT (need for disclosure). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT) since an attempt is made to define the methods and deriving compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, by lacking any technical feature making these claims clear, supported and disclosed, no search has been carried out for claims 35-46.

In addition, a limited search has been executed for claims 1-34 since it is not clear how and to what extent '...or part of the nucleotide sequence...' or '...or part of the amino acid sequence...' should be interpreted and be limited. From the description and the examples given, it appears that what is meant, is a mutated form of the IFNalpha-21 gene and its encoded gene product, provided they comprise at least one of the polymorphisms as claimed. However, present claims 1-34, comprising the wording '...or part of...' relate to an extremely large number of possible gene or polypeptide fragments. In fact, the claims contain so many possible permutations that a lack of clarity and/or conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the whole scope of these claims impossible. Consequently, the search has been limited and carried out to those parts of these claims which do appear to be clear and/or concise and/or supported, namely a mutated IFNalpha-21 gene and its encoded gene product, comprising at least one of the polymorphisms as claimed, as well as methods of genotyping and screening relying on

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

such a mutated gene.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/04082

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8400776	A	01-03-1984	AU 1946283 A CA 1217440 A1 EP 0116090 A1 IT 1172320 B WO 8400776 A1	07-03-1984 03-02-1987 22-08-1984 18-06-1987 01-03-1984
US 4801685	A	31-01-1989	EP 0072541 A2 JP 58041849 A US 4810645 A	23-02-1983 11-03-1983 07-03-1989
WO 0125438	A	12-04-2001	AU 8001300 A CA 2385045 A1 EP 1238082 A2 JP 2003511031 T WO 0125438 A2	10-05-2001 12-04-2001 11-09-2002 25-03-2003 12-04-2001
WO 0039280	A	06-07-2000	US 6350589 B1 US 6433144 B1 EP 1140144 A2 WO 0039280 A2	26-02-2002 13-08-2002 10-10-2001 06-07-2000

This Page Blank (uspto)